

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)


PCT

(10) International Publication Number
WO 2004/000295 A1

- (51) International Patent Classification⁷: **A61K 31/19**,
A61P 3/06, 3/10, C07C 65/24, 233/78, 235/34, 309/66,
311/13, 323/62, C07D 213/40, 217/06, 277/56, 307/68,
233/60
- (72) Inventor; and
(75) Inventor/Applicant (for US only): **LI, Lanna** [SE/SE];
AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).
- (21) International Application Number:
PCT/GB2003/002598
- (74) Agent: **ASTRAZENECA**; Global Intellectual Property,
Mersey, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).
- (22) International Filing Date: 17 June 2003 (17.06.2003)
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0201937-0 20 June 2002 (20.06.2002) SE
- (71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE,
DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM,
GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW only): **ASTRAZENECA**
AB [SE/SE]; Sodertälje, S-151 85 (SE).
- (84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for MG only): **ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).
- Published:
— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

[Continued on next page]

(54) Title: BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA



(57) Abstract: A compound of formula (I) wherein R¹ represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group -(CH₂)_m-T-(CH₂)_n-U-(CH₂)_p- is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH₂)₂, O(CH₂)₃, NC(O)NR⁴(CH₂)₂, CH₂S(O₂)NR⁵(CH₂)₂, CH₂N(R⁶)C(O)CH₂, (CH₂)₂N(R⁶)C(O)(CH₂)₂, C(O)NR⁷CH₂, C(O)NR⁷(CH₂)₂, and CH₂N(R⁶)C(O)CH₂O; V represents O, S, NR⁸, or a single bond; q represents 1, 2 or 3; W represents O, S, N(R⁹)C(O), NR¹⁰, or a single bond; R² represents halo, a C₁₋₄ alkyl group which is optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group which is optionally substituted by one or more fluoro, a C₁₋₄ acyl group, aryl, an aryl C₁₋₄ alkyl group, CN or NO₂; r represents 0, 1, 2 or 3; R³ represents halo, a C₁₋₄ alkyl group which is optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group which is optionally substituted by one or more fluoro, a C₁₋₄ acyl group, aryl, an aryl C₁₋₄ alkyl group, or CN; s represents 0, 1, 2 or 3; and R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ independently represent H, a C₁₋₁₀ alkyl group, aryl or an aryl C₁₋₄ alkyl group or when m is 0 and T represents a group N(R⁹)C(O) or a group (R⁵)NS(O₂) then R¹ and R⁶ or R¹ and R⁵ together with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA

Field of the invention

The present invention relates to certain novel benzoic acid derivatives, to processes for
5 preparing such compounds, to their utility in treating clinical conditions associated with
insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions
containing them.

Background of the invention

10 The Insulin Resistance Syndrome (IRS) including type 2 diabetes mellitus, which refers to
a cluster of manifestations including insulin resistance with accompanying
hyperinsulinaemia, possible type 2 diabetes mellitus, arterial hypertension, central
(visceral) obesity, dyslipidaemia observed as deranged lipoprotein levels typically
15 characterised by elevated VLDL (very low density lipoproteins), small dense LDL
particles and reduced HDL (high density lipoprotein) concentrations and reduced
fibrinolysis.

Recent epidemiological research has documented that individuals with insulin resistance
20 run a greatly increased risk of cardiovascular morbidity and mortality, notably suffering
from myocardial infarction and stroke. In type 2 diabetes mellitus atherosclerosis related
conditions cause up to 80% of all deaths.


In clinical medicine there is awareness of the need to increase the insulin sensitivity in IRS
25 suffering patients and thus to correct the dyslipidaemia which is considered to cause the
accelerated progress of atherosclerosis. However, currently this is not a universally well
defined disease.

Compounds which are modulators of peroxisome proliferator-activated receptors
30 (PPAR, for a review of the PPARs see T. M. Willson et al, J Med Chem 2000, Vol 43,
527) are effective in treating conditions associated with insulin resistance.

Surprisingly a series of compounds has now been found which are modulators of PPAR α and/or PPAR γ activity.

5 Description of the invention

The present invention provides a compound of formula I



10 wherein

R¹ represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted by one or more of the following groups:

a C₁₋₆alkyl group;

15 a C₁₋₆acyl group;

arylC₁₋₆alkyl, wherein the alkyl, aryl, or alkylaryl group is optionally substituted by one or more R^b;

halogen,

-CN and NO₂,

20 -NR^cCOOR^a;

-NR^cCOR^a;

-NR^cR^a;

-NR^cSO₂R^d;

-NR^cCONR^kR^c;

25 -NR^cCSNR^aR^k;

-OR^a;

-OSO₂R^d;

-SO₂R^d;

-SOR^d;

-SR^c;

-SO₂NR^aR^f;

5 -SO₂OR^a;

-CONR^cR^a;

-OCONR^fR^a;

wherein R^a represents H, a C₁₋₆alkyl group, aryl or arylC₁₋₆alkyl group wherein the alkyl,

aryl or arylC₁₋₆alkyl group is optionally substituted one or more times by R^b, wherein R^b

10 represents C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, cyano, -NR^cR^d, =O, halo, -OH, -SH, -OC₁₋₄alkyl, -

Oaryl, -OC₁₋₄alkylaryl, -COR^c, -SR^d, -SOR^d, or -SO₂R^d, wherein R^c represents H, C₁₋

4alkyl, aryl, arylC₁₋₄alkyl and R^d represents C₁₋₄alkyl, aryl, arylC₁₋₄alkyl;

wherein R^f represents hydrogen, C₁₋₄alkyl, C₁₋₄acyl, aryl, arylC₁₋₄alkyl and R^a is as defined

above; and

15 R^k represents hydrogen, C₁₋₄alkyl, aryl, arylC₁₋₄alkyl;

the group -(CH₂)_m-T-(CH₂)_n-U-(CH₂)_p- is attached at either the 3 or 4 position in the

phenyl ring as indicated by the numbers in formula I and represents a group selected from

one or more of the following: O(CH₂)₂, O(CH₂)₃, NC(O)NR⁴(CH₂)₂, CH₂S(O₂)NR⁵(CH₂)₂,

20 CH₂N(R⁶)C(O)CH₂, (CH₂)₂N(R⁶)C(O)(CH₂)₂, C(O)NR⁷CH₂, C(O)NR⁷(CH₂)₂, and

CH₂N(R⁶)C(O)CH₂O;

V represents O, S, NR⁸, or a single bond;

25 q represents 1, 2 or 3 ;

W represents O, S, $N(R^9)C(O)$, NR^{10} , or a single bond;

R^2 represents halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a C_{1-4} alkoxy group which is optionally substituted by one or more fluoro, a C_{1-4} acyl group, aryl, an aryl C_{1-4} alkyl group, CN or NO_2 ;

r represents 0, 1, 2 or 3;

R^3 represents halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a C_{1-4} alkoxy group which is optionally substituted by one or more fluoro, a C_{1-4} acyl group, aryl, an aryl C_{1-4} alkyl group, or CN;

s represents 0, 1, 2 or 3; and

R^4 , R^5 , R^6 , R^7 , R^8 , R^9 and R^{10} independently represent H, a C_{1-10} alkyl group, aryl or an aryl C_{1-4} alkyl group or when m is 0 and T represents a group $N(R^6)C(O)$ or a group $(R^5)NS(O_2)$ then R^1 and R^6 or R^1 and R^5 together with the nitrogen atom to which they are attached represent a heteroaryl group;

and pharmaceutically acceptable salts thereof;

with the provisos that when

1) when R^1 is phenyl optionally substituted by one or two groups independently selected from halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a C_{1-4} alkoxy group which is optionally substituted by one or more fluoro;

m is 1;

T is $N(R^6)C(O)$ wherein R^6 represents a C_{2-8} alkyl group which is optionally interrupted by oxygen;

n is 1;

U is absent or represents methylene;

p is 0;

r is 0;

V is O or S;

q is 1; and

W is a single bond attached to the position ortho to the carboxylic acid group;
then s does not represent 0; and

2) when R^1 is phenyl optionally substituted by one or two groups independently selected
5 from halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a
 C_{1-4} alkoxy group which is optionally substituted by one or more fluoro;

m is 1;

T is $N(R^6)C(O)$ wherein R^6 represents an unbranched C_{2-7} alkyl group;

n is 1;

10 U is O;

p is 0;

r is 0 or 1;

and when r is 1 R^2 is attached at the 3 position and is OCH_3 ;

V is a single bond;

15 q is 2; and

W is O or S attached to the position ortho to the carboxylic acid group;

then s does not represent 0.

Examples of C_{1-6} alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-
20 butyl, t-butyl and straight- and branched-chain pentyl and hexyl as well as cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl. Preferred alkyl groups are methyl, ethyl, propyl,
isopropyl and tertiary butyl.

Unless otherwise stated or indicated, the term "halogen" shall mean fluorine, chlorine,
bromine or iodine, preferably fluorine.

25 Unless otherwise stated or indicated, the term "aryl" denotes a substituted or unsubstituted
phenyl or a fused ring system such as naphthyl.

Unless otherwise stated or indicated, the term "a heterocyclic group" is a saturated,
partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at
least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise
30 specified, be carbon or nitrogen linked, wherein a $-CH_2-$ group can optionally be replaced
by a $-C(O)-$ and a ring sulphur atom may be optionally oxidised to form the S-oxide(s).

Examples and suitable values of the term "heterocyclic group" are morpholino, piperidyl,

pyridyl, pyranlyl, pyrrolyl, imidazolyl, thiazolyl, indolyl, quinolyl, isoquinolyl, thienyl, 1,3-benzodioxolyl, 1,3-dioxolanyl, thiadiazolyl, piperazinyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, pyrrolidinyl, 2-oxazolidinonyl, 5-isoxazolonyl, benz-3-azepinyl, 1,4-benzodioxanyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, 5 3-pyrazolin-5-onyl, tetrahydropyranlyl, benzimidazolyl, benzthiazolyl, imidazo[1,2-a]pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, dihydroisoquinol-2(1H)-yl, 2,3-dihydro-1,5-benzothiazepin-4(5H)-one. Preferably a "heterocyclic group" is pyridyl, imidazolyl, thiazolyl, quinolyl, thienyl, 1,3-benzodioxolyl, 1,3-dioxolanyl, isothiazolidinyl, 10 1,3,4-triazolyl, tetrazolyl, 2-oxazolidinonyl, 5-isoxazolonyl, benz-3-azepinyl, hydantoinyl, 1,4-benzodioxanyl, thiomorpholino, 3-pyrazolin-5-onyl, benzimidazolyl, benzthiazolyl, imidazo[1,2-a]pyridyl, pyrimidyl, pyrazinyl, and 2,3-dihydro-1,5-benzothiazepin-4(5H)-one.

15 Further values of R^1 , T, U, V, W, R^2 , R^3 , m, n, p, q, r and s in compounds of Formula I now follow. It will be understood that such values may be used with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

In a first aspect R^1 represents phenyl which is optionally substituted by one or more of the following: halo, hydroxy, a C_{1-4} alkyl group which is optionally substituted by one or more 20 fluoro, a C_{1-4} alkoxy group which is optionally substituted by one or more fluoro, benzyloxy, a C_{1-4} alkylsulphonyloxy group, phenyl or a heteroaryl group, or R^1 represents a heterocyclic group which is optionally substituted by one or more of the following: halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a C_{1-4} alkoxy group which is optionally substituted by one or more fluoro or phenyl optionally 25 substituted by one or more of the following: halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a C_{1-4} alkoxy group which is optionally substituted by one or more fluoro. In particular R^1 represents phenyl, furyl, pyridyl or thiazolyl each of which is optionally substituted by one or more of the following: halo (particularly fluoro), a 30 C_{1-4} alkyl group, trifluoromethyl, a C_{1-4} alkoxy group, methanesulphonyloxy, hydroxy, benzyloxy, imidazolyl or phenyl.

In a second aspect the group $-(CH_2)_m-T-(CH_2)_n-U-(CH_2)_p-$ is attached at the 4 position in the phenyl ring as indicated by the numbers in formula I, that is para to the group V.

- 5 In a third aspect the group $-V-(CH_2)_q-W-$ represents a group selected from one or more of the following: OCH_2 , SCH_2 , $NHCH_2$, CH_2CH_2S or CH_2CH_2O .

In a fourth aspect the group $-V-(CH_2)_q-W-$ represents the group OCH_2 .

- 10 In a fifth aspect the group $-V-(CH_2)_q-W-$ is joined at the ortho position with respect to the carboxylic acid group.

In a sixth aspect R^2 is halo, a C_{1-4} alkyl group or a C_{1-4} alkoxy group and r is 0 or 1.

In a seventh aspect s is 0.

- It will be appreciated by those skilled in the art that certain compounds of formula I may
15 contain an optically active centre and therefore can exist as enantiomers which can be separated as described later. It is expected that most, if not all, of the activity of the compounds of formula I resides in one enantiomer: either the S or the R enantiomer or the (+) or the (-) enantiomer. The enantiomers which are more active in the assays which are described later are preferred forms of the present invention. It will be understood that the
20 present invention includes all mixtures of this active enantiomer with the other enantiomer, for example the racemic mixture.

- The active enantiomers may be isolated by separation of racemate for example by fractional crystallization, resolution or HPLC on a chiral column (for example a
25 Chiralpak™ AD 250x50 column). Alternatively the active enantiomers may be made by chiral synthesis from chiral starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation with a chiral reagent.

- Prodrugs of the compounds of formula I also form part of the present invention. The term
30 "prodrug" as used in this specification includes derivatives of the carboxylic acid group which are converted in a mammal, particularly a human, into the carboxylic acid group or a salt or conjugate thereof. It should be understood that, whilst not being bound by theory,

it is believed that most of the activity associated with the prodrugs arises from the activity of the compound of formula I into which the prodrugs are converted. Prodrugs can be prepared by routine methodology well within the capabilities of someone skilled in the art. Various prodrugs of carboxy are known in the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology. 42: 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p.113-191 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8:1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77:285 (1988); and
- e) N. Kakeya, *et al.*, Chem Pharm Bull, 32:692 (1984).

The above documents a to e are herein incorporated by reference.

In vivo cleavable esters are just one type of prodrug of the parent molecule.

The compounds of formula I have activity as medicaments. In particular the compounds of formula I are selective agonists of either PPAR α or PPAR γ , particularly of PPAR α , or are agonists of PPAR α and PPAR γ . The term agonists as used herein, includes partial agonists.

The present invention provides one or more compounds selected from:

- 3-{[(3-{[(1,1'-biphenyl-4-ylcarbonyl)amino]methyl}phenyl)amino]methyl}benzoic acid;
- 2-{[4-(2-oxo-2-{[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]methyl}benzoic acid;
- 2-[(3-{2-[benzyl(hexyl)amino]-2-oxoethyl}phenoxy)methyl]benzoic acid;
- 2-{[3-(2-oxo-2-{[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]methyl}benzoic acid;
- 2-[(4-{3-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-3-oxopropyl}phenoxy)-methyl]benzoic acid;
- 2-[(4-{2-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)carbonyl]amino}-ethyl)phenoxy]methyl]benzoic acid;
- 2-[(4-{2-[(2,4-difluorophenyl)amino]carbonyl}amino)ethyl]phenoxy)methyl]benzoic acid;


2-[(4-{2-[(2-methyl-5-phenyl-3-furoyl)amino]ethyl}phenoxy)methyl]benzoic acid;
 2-[(4-{2-[(benzylsulfonyl)amino]ethyl}phenoxy)methyl]benzoic acid;
 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-fluorophenoxy)methyl]benzoic acid;
 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-methoxyphenoxy)methyl]benzoic acid;
 5 2-[(4-{3-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-oxopropyl}phenoxy)methyl]benzoic acid;
 2-[(4-{2-[4-(1*H*-imidazol-1-yl)phenoxy]ethyl}-phenoxy)methyl]benzoic acid;
 2-[(4-{2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl}phenoxy)methyl]benzoic acid;
 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoic acid;
 2-[(3-{2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl}phenoxy)methyl]benzoic acid;
 10 2-[(3-{2-(4-hydroxyphenoxy)ethyl}phenoxy)methyl]benzoic acid;
 2-[(4-{3-[4-(benzyloxy)phenoxy]propyl}phenoxy)methyl]benzoic acid;
 2-[(4-{3-[4-[(methylsulfonyl)oxy]phenoxy]propyl}phenoxy)methyl]benzoic acid;
 2-[(4-{3-(4-hydroxyphenoxy)propyl}phenoxy)methyl]benzoic acid;
 2-[(4-{3-[2-(2-ethoxyphenyl)ethyl]amino}-3-oxopropyl)phenoxy)methyl]benzoic acid;
 15 2-[(4-{3-[ethyl(2-pyridin-2-ylethyl)amino]-3-oxopropyl}phenoxy)methyl]benzoic acid;
 2-[(2-{3-{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)ethyl}thio]benzoic acid;
 2-[(4-{2-[heptyl[2-(2-methoxyphenyl)ethyl]amino]-2-oxoethyl}phenoxy)methyl]benzoic
 acid;
 20 2-[(4-{2-[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}phenoxy)methyl]benzoic
 acid;
 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}-phenoxy)methyl]benzoic acid;
 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenoxy)methyl]benzoic acid;
 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethyl}benzyl)oxy]benzoic acid;
 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}benzyl)oxy]benzoic acid;
 25 2-[(2-[4-(2-{isobutyl[4-(trifluoromethyl)benzyl]amino]-2-oxoethoxy}phenyl)ethoxy]-
 benzoic acid; and
 2-[(4-{2-[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}benzyl)oxy]benzoic acid
 and pharmaceutically acceptable salts thereof.

It will also be understood that certain compounds of the present invention may exist in
 30 solvated as well as unsolvated forms. It is to be understood that the present invention
 encompasses all such solvated forms. Certain compounds of the present invention may

exist as tautomers. It is to be understood that the present invention encompasses all such tautomers.

Methods of preparation

The compounds of the invention may be prepared as outlined below. However, the invention is not limited to these methods, the compounds may also be prepared as described for structurally related compounds in the prior art. The reactions can be carried out according to standard procedures or as described in the experimental section. Compounds of formula I may be prepared by reacting a compound of formula II



II

in which R^1 , T, U, V, W, R^2 , R^3 , m, n, p, q, r and s are as previously defined and PG represents a protecting group for a carboxylic hydroxy group as described in the standard text "Protective Groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts, with a de-protecting agent. The protecting group may also be a resin, such as Wang resin or 2-chlorotrityl chloride resin. Protecting groups may be removed in accordance to techniques which are well known to those skilled in the art. One such protecting group is where PG represents C_{1-6} alkoxy group or an arylalkoxy group eg benzyloxy, such that COPG represents an ester. Such esters can be reacted with a hydrolysing agent, for example lithium hydroxide in the presence of a solvent for example a mixture of THF and water or potassium hydroxide in a C_{1-3} alcohol for example methanol, at a temperature in the range of 0-200°C or by microwave radiation to give compounds of formula I.


Compounds of formula II may be prepared according to one the following routes 1 to 5. It will be appreciated by those skilled in the art that methods analogous to those given in routes 1 to 5 may be used to prepare intermediates for compounds of Formula I in which R^1 is a heterocyclic group. Also analogous routes to routes 1 to 5 may be used to prepare

11


compounds of Formula I in which the oxygen atom in the linking chains is replaced by S

or NR.


route 1




route 2




route 3



route 4




route 5




Starting amines may be prepared as described in Ralph N Salvatore et al Tetrahedron, 57, 7785-7811,2001or by the methods given below.

13


1. Making amide then reduction.



2. reductive amination



3. N-alkylation



Compounds of formula II are believed to be novel and are claimed herein as useful intermediates in the preparation of compounds of formula I.

The compounds of the invention may be isolated from their reaction mixtures using conventional techniques.

Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative and in some occasions, more convenient manner, the individual process steps mentioned hereinbefore may be performed in different order, and/or the individual reactions may be performed at different stage in the overall route (i.e. chemical transformations may be performed upon different intermediates to those associated hereinbefore with a particular reaction).

In any of the preceding methods of preparation, where necessary, hydroxy, amino or other reactive groups may be protected using a protecting group, R^P as described in the standard text "Protective groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts.

The protecting group may also be a resin, such as Wang resin or 2-chlorotriyl chloride resin. The protection and deprotection of functional groups may take place before or after any of the reaction steps described hereinbefore. Protecting groups may be removed in accordance to techniques which are well known to those skilled in the art.

The expression "inert solvent" refers to a solvent which does not react with the starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.

Pharmaceutical preparations

The compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient either as a free acid, or a pharmaceutically acceptable salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.

Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.0001-100 mg/kg body weight, preferably 0.001-10 mg/kg body weight.

Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.5mg to 500mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25mg, 50mg, 100mg and 250mg.

According to a further aspect of the invention there is thus provided a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.

5

Pharmacological properties

The present compounds of formula (I) are useful for the prophylaxis and/or treatment of clinical conditions associated with inherent or induced reduced sensitivity to insulin
10 (insulin resistance) and associated metabolic disorders (also known as metabolic syndrome). These clinical conditions will include, but will not be limited to, general obesity, abdominal obesity, arterial hypertension, hyperinsulinaemia, hyperglycaemia, type 2 diabetes and the dyslipidaemia characteristically appearing with insulin resistance. This dyslipidaemia, also known as the atherogenic lipoprotein profile, is characterised by
15 moderately elevated non-esterified fatty acids, elevated very low density lipoprotein (VLDL) triglyceride rich particles, high Apo B levels, low high density lipoprotein (HDL) levels associated with low apoAI particle levels and high Apo B levels in the presence of small, dense, low density lipoproteins (LDL) particles, phenotype B.

20 The compounds of the present invention are expected to be useful in treating patients with combined or mixed hyperlipidemias or various degrees of hypertriglyceridemias and postprandial dyslipidemia with or without other manifestations of the metabolic syndrome.

Treatment with the present compounds is expected to lower the cardiovascular morbidity
25 and mortality associated with atherosclerosis due to their antidyslipidaemic as well as antiinflammatory properties. The cardiovascular disease conditions include macro-angiopathies of various internal organs causing myocardial infarction, congestive heart failure, cerebrovascular disease and peripheral arterial insufficiency of the lower extremities. Because of their insulin sensitizing effect the compounds of formula I are also
30 expected to prevent or delay the development of type 2 diabetes from the metabolic syndrome and diabetes of pregnancy. Therefore the development of long-term complications associated with chronic hyperglycaemia in diabetes mellitus such as the

micro-angiopathies causing renal disease, retinal damage and peripheral vascular disease of the lower limbs are expected to be delayed. Furthermore the compounds may be useful in treatment of various conditions outside the cardiovascular system whether or not associated with insulin resistance, like polycystic ovarian syndrome, obesity, cancer and states of inflammatory disease including neurodegenerative disorders such as mild
5 cognitive impairment, Alzheimer's disease, Parkinson's disease and multiple sclerosis.

The compounds of the present invention are expected to be useful in controlling glucose levels in patients suffering from type 2 diabetes.

10 The present invention provides a method of treating or preventing dyslipidemias, the insulin resistance syndrome and/or metabolic disorders (as defined above) comprising the administration of a compound of formula I to a mammal (particularly a human) in need thereof.

15 The present invention provides a method of treating or preventing type 2 diabetes comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.

20 In a further aspect the present invention provides the use of a compound of formula I as a medicament.

In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment of insulin resistance and/or metabolic
25 disorders.

Combination Therapy

The compounds of the invention may be combined with another therapeutic agent that is
30 useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity. The compounds of the invention may be combined with another therapeutic agent

that decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol. In patients with diabetes mellitus the compounds of the invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.

5

The compounds of the invention may be used alongside other therapies for the treatment of metabolic syndrome or type 2 diabetes and its associated complications, these include biguanide drugs, for example metformin, phenformin and buformin, insulin (synthetic insulin analogues, amylin) and oral antihyperglycemics (these are divided into prandial
10 glucose regulators and alpha-glucosidase inhibitors). An example of an alpha-glucosidase inhibitor is acarbose or voglibose or miglitol. An example of a prandial glucose regulator is repaglinide or nateglinide.

In another aspect of the invention, the compound of formula I, or a pharmaceutically
15 acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with another PPAR modulating agent. PPAR modulating agents include but are not limited to a PPAR alpha and/or gamma and /or delta agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts, solvates, solvates of such salts
20 or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO 98/57941, WO 01/40170, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all incorporated herein by
25 reference. Particularly a PPAR alpha and/or gamma agonist refers to BMS 298585, clofibrate, fenofibrate, bezafibrate, gemfibrozil and ciprofibrate; GW 9578, pioglitazone, rosiglitazone, rivoglitazone, balaglitazone, KRP-297, JTT-501, SB 213068, GW 1929, GW 7845, GW 0207, L-796449, L-165041 and GW 2433. Particularly a PPAR alpha and/or gamma agonist refers to (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxy-
30 phenyl}ethoxy)phenyl]propanoic acid and pharmaceutically acceptable salts thereof.

In addition the combination of the invention may be used in conjunction with a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, gliquidone, chlorpropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolcyclamide and tolazamide. Preferably the sulfonylurea is glimepiride or glibenclamide (glyburide). More preferably the sulfonylurea is glimepiride. Therefore the present invention includes administration of a compound of the present invention in conjunction with one, two or more existing therapies described in this paragraph. The doses of the other existing therapies for the treatment of type 2 diabetes and its associated complications will be those known in the art and approved for use by regulatory bodies for example the FDA and may be found in the Orange Book published by the FDA.

Alternatively smaller doses may be used as a result of the benefits derived from the combination. The present invention also includes a compound of the present invention in combination with a cholesterol-lowering agent. The cholesterol-lowering agents referred to in this application include but are not limited to inhibitors of HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase). Suitably the HMG-CoA reductase inhibitor is a statin selected from the group consisting of atorvastatin, bervastatin, cerivastatin, dalvastatin, fluvastatin, itavastatin, lovastatin, mevastatin, nicostatin, nivastatin, pravastatin and simvastatin, or a pharmaceutically acceptable salt, especially sodium or calcium, or a solvate thereof, or a solvate of such a salt. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A particularly preferred statin is, however, a compound with the chemical name (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, [also known as (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-(methylsulfonyl)-amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt. The compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, and its calcium and sodium salts are disclosed in European Patent Application, Publication No. EP-A-0521471, and in Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444. This latter statin is now known under its generic name rosuvastatin.

In the present application, the term "cholesterol-lowering agent" also includes chemical modifications of the HMG-CoA reductase inhibitors, such as esters, prodrugs and metabolites, whether active or inactive.

5

The present invention also includes a compound of the present invention in combination with a bile acid sequestering agent, for example colestipol or cholestyramine or cholestagel.

10 The present invention also includes a compound of the present invention in combination with an inhibitor of the ileal bile acid transport system (IBAT inhibitor).

Suitable compounds possessing IBAT inhibitory activity have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO
15 94/24087, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO98/07749, WO 98/38182, WO 98/40375, WO 98/56757, WO 99/32478, WO 99/35135, WO 99/64409, WO 99/64410, WO 00/01687, WO 00/20392, WO 00/20393, WO 00/20410, WO 00/20437, WO 01/34570, WO 00/35889, WO 00/47568, WO 00/61568, WO 01/68637, WO 01/68096, WO 02/08211, WO 00/38725, WO 00/38726, WO 00/38727,
20 WO 00/38728, WO 00/38729, DE 19825804, JP 10072371, US 5070103, EP 251 315, EP 417 725, EP 489 423, EP 549 967, EP 573 848, EP 624 593, EP 624 594, EP 624 595, EP 869 121, EP 864 582, and EP 1 070 703, and the contents of these patent applications, particularly the compounds described in claim 1 and the named examples, are incorporated herein by reference.

25

Particular classes of IBAT inhibitors suitable for use in the present invention are benzothiepinines, and the compounds described in the claims, particularly claim 1, of WO 00/01687, WO 96/08484 and WO 97/33882 are incorporated herein by reference. Other suitable classes of IBAT inhibitors are the 1,2-benzothiazepines, 1,4-benzothiazepines and
30 1,5-benzothiazepines. A further suitable class of IBAT inhibitors is the 1,2,5-benzothiadiiazepines.

One particular suitable compound possessing IBAT inhibitory activity is (3*R*,5*R*)-3-butyl-3-ethyl-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl β -D-glucopyranosiduronic acid (EP 864 582). Other suitable IBAT inhibitors include one of:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(carboxymethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N'*-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-2-fluorobenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{(R)-1-[*N''*-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]-2-hydroxyethyl}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{ α -[*N'*-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{ α -[*N'*-(ethoxy)(methyl)phosphoryl-methyl]carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{2-[(hydroxy)(methyl)phosphoryl]ethyl}carbamoyl)benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N'*-(2-methylthio-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{2-[(methyl)(ethyl)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{*N*-[(R)- α -(*N'*-{2-[(methyl)(hydroxy)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[(R)-*N'*-(2-methylsulphinyl-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8-[*N*-{(R)- α -[*N'*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-{(S)-1-[*N*-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-((R/S)- α -{*N*-[1-(R)-2-(S)-1-hydroxy-1-(3,4-dihydroxyphenyl)prop-2-yl]carbamoyl}-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from:

a CETP (cholesteryl ester transfer protein) inhibitor, for example those referenced and described in WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference;

a cholesterol absorption antagonist for example azetidinones such as SCH 58235 and those described in US 5,767,115 which are incorporated herein by reference;

a MTP (microsomal transfer protein) inhibitor for example those described in Science, 282, 751-54, 1998 which are incorporated herein by reference;

a nicotinic acid derivative, including slow release and combination products, for example, nicotinic acid (niacin), acipimox and niceritrol;

a phytosterol compound for example stanols;

probucol;

an omega-3 fatty acid for example OmacorTM;

an anti-obesity compound for example orlistat (EP 129,748) and sibutramine (GB

5 2,184,122 and US 4,929,629);

an antihypertensive compound for example an angiotensin converting enzyme (ACE)

inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha

andrenergic blocker, a beta andrenergic blocker for example metoprolol, a mixed

alpha/beta andrenergic blocker, an andrenergic stimulant, calcium channel blocker, an AT-

10 1 blocker, a saluretic, a diuretic or a vasodilator;

a CB1 antagonist or inverse agonist for example as described in WO01/70700 and EP

65635 ;

aspirin;

a Melanin concentrating hormone (MCH) antagonist;

15 a PDK inhibitor; or

modulators of nuclear receptors for example LXR, FXR, RXR, and RORalpha;

or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof,

optionally together with a pharmaceutically acceptable diluent or carrier to a warm-

blooded animal, such as man in need of such therapeutic treatment.

20

Particular ACE inhibitors or pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof, including active metabolites, which can be used in combination with a compound of formula I include but are not limited to, the following compounds:

alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride,

25 benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione,

ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril,

enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium,

fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4,

idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B,

30 mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C,

pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride,

quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril,

spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril and zofenoprilat. Preferred ACE inhibitors for use in the present invention are ramipril, ramiprilat, lisinopril, enalapril and enalaprilat. More preferred ACE inhibitors for uses in the present invention are ramipril
5 and ramiprilat.

Preferred angiotensin II antagonists, pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof for use in combination with a compound of formula I include, but are not limited to, compounds: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan. Particularly preferred
10 angiotensin II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil.

Therefore in an additional feature of the invention, there is provided a method for for the treatment of type 2 diabetes and its associated complications in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of one the other compounds described in this
15 combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a
25 compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of one the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

30

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable

salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

5

According to a further aspect of the present invention there is provided a kit comprising a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

10

According to a further aspect of the present invention there is provided a kit comprising:

a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;

15

b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and

c) container means for containing said first and second dosage forms.

20

According to a further aspect of the present invention there is provided a kit comprising:

a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;

25

b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and

c) container means for containing said first and second dosage forms.

30

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in

the manufacture of a medicament for use in the the treatment of metabolic syndrome or type 2 diabetes and its associated complications in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of
5 the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

10 According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the
15 simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

20 Working examples

^1H NMR and ^{13}C NMR measurements were performed on a Varian Mercury 300 or Varian UNITY plus 400, 500 or 600 spectrometers, operating at ^1H frequencies of 300, 400, 500 and 600 MHz, respectively, and at ^{13}C frequencies of 75, 100, 125 and 150 MHz,
25 respectively. Measurements were made on the delta scale (δ).

Unless otherwise stated, chemical shifts are given in ppm with the solvent as internal standard.

Abbreviations

30 IRS insulin resistance syndrome
TLC thin layer chromatography
HOBtxH₂O 1-hydroxybenzotriazole-hydrate

	DIBAH	diisobutylaluminium hydride
	DMSO	dimethyl sulfoxide
	EtOAc	ethyl acetate
	DMF	<i>N,N</i> -dimethylformamide
5	THF	tetrahydrofuran
	HPLC	high performance liquid chromatography
	MeCN	acetonitrile
	TFA	trifluoroacetic acid
	Pd/C	palladium on charcoal
10	HATU	O-(7-azabenzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate
	DCM	dichloromethane
	NH ₄ OAc	ammonium acetate
	MeOH	Methanol
15	DIPEA	<i>N,N</i> -diisopropylethylamine
	DMAP	4-dimethylaminopyridine
	Trisamine	Tris(hydroxymethyl)aminomethane
	TBTU	O-(benzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium tetrafluoroborate
	EDC	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
20	NH ₄ OAc	ammonium acetate
	LC-MS	liquid chromatography- mass spectroscopy
	ISOLUTE ® FLASH Si is a silica column suitable for chromatography	
	Borohydride on polymer support is Borohydride on Amberlite IRA-400 available from Aldrich	
25	t	triplet
	s	singlet
	d	doublet
	q	quartet
	qvint	quintet
30	m	multiplet
	br	broad
	bs	broad singlet

dm doublet of multiplet
bt broad triplet
dd doublet of doublet

5 Example 1

a) *tert*-Butyl 3-{[(1,1'-biphenyl-4-ylcarbonyl)amino]methyl}phenylcarbamate

Biphenyl-4-carboxylic acid (981 mg, 4.949 mmol) and 3-(aminomethyl)-1-N-boc-aniline (1.0 g, 4.499 mmol) were mixed in DMF (10 ml). Under stirring, benzotriazol-1-yl-oxytri-
10 pyrrolidinophosphonium hexafluorophosphate (2.343 g, 4.504 mmol) was added and then N,N-diisopropylethylamine (1.164 g, 9.007 mmol) was added. The mixture was stirred overnight at room temperature. Water and ethyl acetate were added. The organic phase was washed with water, sodium hydrogencarbonate (sat.) and water (x2) and dried with magnesium sulphate. The solvent was removed. Diethyl ether was added into the residue.
15 The solid product was filtered, washed with little diethyl ether and dried, 1.44g product was obtained. The filtrate was evaporated to dryness. DCM was added to the residue. Filtration gave 0.12 g more solid product. In total 1.56 g desired product was obtained, yield 86%.

¹H NMR (400 MHz, CDCl₃): δ 3.61(s, 9H), 4.66 (d, 2H), 6.43 (s, br, 1H), 6.50 (s, 1H),
20 7.06-7.09 (m, 1H), 7.27-7.30 (m, 2H), 7.38-7.50 (m, 4H), 7.61-7.64 (m, 2H), 7.67 (d, 2H) and 7.88 (2H).

b) *N*-(3-Aminobenzyl)-1,1'-biphenyl-4-carboxamide

25 *tert*-Butyl 3-{[(1,1'-biphenyl-4-ylcarbonyl)amino]methyl}phenylcarbamate (250 mg, 0.6 mmol) was dissolved in DCM (10 ml). Trifluoroacetic acid (0.2 ml) was added. The mixture was stirred overnight. HPLC showed that more than 50% of the starting material was not reacted. More trifluoroacetic acid (0.3 ml) was added. The mixture was stirred overnight again. Water was added into the mixture. The phases were not clear. DCM was
30 evaporated in vacuum. Ethyl acetate was added to the residue. The obtained organic phase was washed with water (x3) and dried with magnesium sulphate. The solvent was then evaporated. Solid product (185 mg) was obtained, yield 99%.

¹H NMR (500 MHz, CD₃OD): δ 4.64 (s, 2H), 7.27 (d, 1H), 7.37-7.40 (m, 2H), 7.45-7.53 (m, 4H), 7.66 (d, 2H), 7.74 (d, 2H) and 7.95 (d, 2H).

c) 3-([(3-([(1,1'-Biphenyl-4-ylcarbonyl)amino]methyl)phenyl)amino]methyl)benzoic acid

5

N-(3-aminobenzyl)-1,1'-biphenyl-4-carboxamide (20 mg, 0.07 mmol) was dissolved in acetic acid (0.5 ml). 3-Carboxybenzaldehyde (14 mg, 0.09 mmol) was added and then sodium borohydride (11 mg, 0.28 mmol) was added. The mixture was stirred at room temperature for 2 hours and evaporated to dryness. DCM was added into the residue. The mixture was loaded on a column (ISOLUTE® SI, 500 mg/3 ml). It was eluted with DCM, MeOH/DCM (0.5:99.5) and then MeOH/DCM (1:99). The product fractions were combined and the solvent was removed, Re-chromatography of the residue on a column (ISOLUTE® SI, 1 g/6 ml) using DCM, MeOH/DCM (0.5:99.5) and then MeOH/DCM (1:99) as eluant gave 9 mg the desired product, yield 31%.

15 ¹H NMR (500 MHz, CD₃OD): δ 4.37 (s, 2H), 4.46 (d, 2H), 6.53 (d, 1H), 6.59-6.61 (m, 2H), 7.04 (t, 1H), 7.30-7.38 (m, 2H), 7.46 (t, 2H), 7.55 (d, 1H), 7.65-7.70 (m, 4H), 7.83 (t, 3H), 8.02 (s, 1H) and 8.80 (br, 1H).

Example 2

20 a) Methyl 2-([4-(2-oxo-2-([4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]methyl)-benzoate

(4-([2-(Methoxycarbonyl)benzyl]oxy)phenyl)acetic acid (50 mg, 0.167 mmol) was dissolved in DCM (2 ml), 4-(Trifluoromethyl)benzylamine (35 mg, 0.2 mmol) was added, then EDC (38 mg, 0.2 mmol) was added and then DMAP (24.4 mg, 0.2 mmol) was added. The mixture was stirred at room temperature overnight. 1% hydrochloric acid (1 ml) and water (1 ml) was added into the mixture. The two phases were separated using a Whatman Filter Tube. The obtained organic solution was evaporated in vacuum and the solid product (72 mg) was left, yield 95%.

30 ¹H NMR (500 MHz, CDCl₃): δ. 3.63 (s, 2H), 3.93 (s, 3H), 4.50 (d, 2H), 5.53 (s, 2H), 5.79 (br, 1H), 7.02 (d, 2H), 7.22 (d, 2H), 7.32 (d, 2H), 7.42 (t, 1H), 7.57-7.61 (m, 3H), 7.77 (d, 1H) and 8.07 (d, 1H).

b) 2-([4-(2-Oxo-2-([4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]methyl)benzoic acid

Methyl 2-([4-(2-oxo-2-([4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]methyl)-
5 benzoate (71 mg, 0.155 mmol) in THF (1.5 ml) was cooled in an ice-bath. Lithium
hydroxide (7.5 mg, 0.310 mmol) in water (1.5 ml) was dropped in. The cooling-bath was
then removed and the mixture was stirred overnight. HPLC showed that the reaction was
not complete. More lithium hydroxide (0.2M, 0.5 ml) was added. The reaction mixture was
stirred for 4 days more. It was then evaporated in vacuum to remove THF. The residue was
10 acidified with 1% hydrochloric acid, pH=3-4, and then extracted with ethyl acetate. The
organic phase was dried with magnesium sulphate and evaporated. Chromatography of the
residue on a column (ISOLUTE® SI, 2g/6 ml) using DCM, MeOH/DCM (0.5:99.5, then
1:99, and then 2:98) as eluant gave 39 mg white solid product, yield 57%.
¹H NMR (500 MHz, CD₃OD): δ 3.50 (s, 2H), 4.42(d, 2H), 5.47 (s, 2H), 6.94 (d, 2H), 7.22
15 (d, 2H), 7.37-7.40 (m, 3H), 7.53-7.58(m, 3H), 7.69 (d, 1H) and 8.01 (d, 1H).

Example 3a) (3-([2-(Methoxycarbonyl)benzyl]oxy)phenyl)acetic acid

20 3-Hydroxyphenylacetic acid (760 mg, 5 mmol) was dissolved in ethanol (99.5%, 20 ml).
Potassium hydroxide (560 mg, 10 mmol) was added. The mixture was stirred for 30
minutes. 2-Bromomethylbenzoic acid methyl ester (1.144 g, 5 mmol) was then dropped in.
The resulting mixture was heated to reflux for 2 hours and then evaporated in vacuum to
dry. Water and ethyl acetate were added into the residue and the phases were separated.
25 The water phase was acidified with 10% hydrochloric acid, pH~5, and then extracted with
ethyl acetate. The organic phase was dried (magnesium sulphate) and evaporated in
vacuum to dry. Chromatography of the residue on a column (ISOLUTE® SI, 5g/25ml)
using DCM, MeOH/DCM (1:99) as eluant gave 213 mg the desired product, yield 14%.
¹H NMR (500 MHz, CDCl₃): δ 3.65 (s, 2H), 3.91 (s, 3H), 5.51 (s, 2H), 6.90-6.96 (m, 3H),
30 7.27 (t, 1H), 7.39 (t, 1H), 7.57 (t, 1H), 7.77 (d, 1H) and 8.04 (d, 1H).

b) Methyl 2-[(3-{2-[benzyl(hexyl)amino]-2-oxoethyl}phenoxy)methyl]benzoate

(3-{[2-(Methoxycarbonyl)benzyl]oxy}phenyl)acetic acid (60 mg, 0.2 mmol) was dissolved in DCM (2 ml), N-hexylbenzylamine (46 mg, 0.24 mmol) was added, then EDC (46 mg, 0.24 mmol) was added and then DMAP (29.3 mg, 0.24 mmol) was added. The mixture was stirred at room temperature overnight. 1% hydrochloric acid (1 ml) and water (1 ml) were added into the mixture. The two phases were separated by using a Whatman Filter Tube. The obtained organic portion was evaporated in vacuum and 59 mg crude oil product was left. It was then used directly in next step.

c) 2-[(3-{2-[Benzyl(hexyl)amino]-2-oxoethyl}phenoxy)methyl]benzoic acid

Methyl 2-[(3-{2-[benzyl(hexyl)amino]-2-oxoethyl}phenoxy)methyl]benzoate (59 mg, 0.125 mmol) in THF (1 ml) was cooled in an ice-bath. Lithium hydroxide (6 mg, 0.249 mmol) in water (1 ml) was dropped in. The cooling-bath was then removed and the mixture was stirred for 13 days and then evaporated in vacuum to remove THF. The residue was acidified with 1% hydrochloric acid, pH~4, and extracted with ethyl acetate. The organic phase was dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 1g/6 ml) using DCM and MeOH/DCM (0.5:99.5, then 1:99) as eluant gave 7 mg the desired product, yield 8% (two steps).

¹H NMR (rotamers, 500 MHz, CDCl₃): δ 0.85-0.90 (m, 3H), 1.20-1.30 (m, 6H), 1.45-1.57 (m, 2H), 3.20, 3.40 (t, t, 2H), 3.70, 3.80 (s, s, 2H), 4.51, 4.65 (s, s, 2H), 5.51, 5.52 (s, s, 2H), 6.83-7.00 (m, 3H), 7.14-7.43 (m, 7H), 7.59 (t, 1H), 7.78 (d, 1H) and 8.13 (d, 1H).

Example 4

a) Methyl 2-[(3-(2-oxo-2-{[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy)methyl]-benzoate

(3-{[2-(Methoxycarbonyl)benzyl]oxy}phenyl)acetic acid (60 mg, 0.2 mmol) was dissolved in DCM (2 ml). 4-(Trifluoromethyl)benzylamine (42 mg, 0.24 mmol) was added, then EDC (46 mg, (0.24 mmol) was added and then DMAP (29.3 mg, 0.24 mmol) was added. The mixture was stirred at room temperature overnight. 1% Hydrochloric acid (1 ml) and

water (1 ml) were added to the mixture. The two phases were separated by using a Whatman Filter Tube. The obtained organic portion was evaporated in vacuum and 82 mg solid product was left. It was then used directly in next step.

5 b) 2-{[3-(2-Oxo-2-{[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]methyl}benzoic acid

Methyl 2-{[3-(2-oxo-2-{[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]methyl}-benzoate (82 mg, 0.18 mmol) in THF (2 ml) was cooled in an ice-bath. Lithium hydroxide (8.6 mg, 0.36 mmol) in water (1 ml) was dropped in. The cooling-bath was then removed
10 and the mixture was stirred for 7 days and then evaporated in vacuum to remove THF. The residue was acidified with 1% hydrochloric acid, pH~3, and extracted with ethyl acetate. The organic phase was dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6 ml) using DCM and MeOH/DCM (1:99, then 2:98) as eluant gave 20 mg the desired product, yield 22.5% (two steps).
15 ¹H NMR (500 MHz, CD₃OD): δ 3.55 (s, 2H), 4.43 (s, 2H), 5.47 (s, 2H), 6.90 (t, 2H), 6.98 (s, 1H), 7.23 (t, 1H), 7.38-7.42 (m, 3H), 7.53-7.59 (m, 3H), 7.70 (d, 1H) and 8.03 (d, 1H).

Example 5a) N-[2-(3,4-dimethoxyphenyl)ethyl]-3-(4-hydroxyphenyl)-N-methylpropanamide

3-(4-Hydroxyphenyl)propionic acid (166.2 mg, 1 mmol) was dissolved in DMF (4 ml). 2-
5 (3,4-Dimethoxyphenyl)-N-methylethylamine (211 mg, 1.05 mmol) was added. The mixture was cooled in an ice-bath. TBTU (337 mg, 1.05 mmol) was added, followed by DIPEA (0.37 ml, 2.1 mmol). The mixture was stirred overnight and the temperature was allowed up to room temperature. Ethyl acetate and sodium hydrogencarbonate aqueous solution (sat.) were added and then the two phases were separated. The water phase was
10 extracted with ethyl acetate. The organic phases were combined and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 5g/15 ml) using DCM and then MeOH/DCM (1:99) as eluant gave 333 mg the desired product, yield 97%.

¹H NMR (rotamers, 500 MHz, CDCl₃): δ 2.35, 2.59 (t, t, 2H), 2.71-2.80, 2.90 (m, t, 4H),
15 2.84, 2.97 (s, s, 3H), 3.45, 3.58 (t, t, 2H), 3.84-3.86 (m, 6H), 6.61-6.83 (m, 4H), 6.95 (d, 1H), 7.05 (d, 1H) and 7.50, 7.56 (s, s, 1H).

b) Methyl 2-[(4-{3-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-3-oxopropyl}phenoxy)methyl]benzoate

20 N-[2-(3,4-dimethoxyphenyl)ethyl]-3-(4-hydroxyphenyl)-N-methylpropanamide (198 mg, 0.577 mmol), 2-bromomethyl-benzoic acid methyl ester (139 mg, 0.605 mmol) and potassium carbonate, anhydrous (120 mg, 0.864 mmol) were mixed in acetonitrile (15 ml). The mixture was heated to reflux overnight and then evaporated to dry. Water and ethyl
25 acetate were added and the two phases were separated. The organic phase was dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6ml) using heptane/DCM (50:50), then DCM and then MeOH/DCM (0.5:99.5) as eluant gave 172 mg the desired product, yield 61%.

¹H NMR (rotamers, 500 MHz, CDCl₃): 2.34, 2.58 (t, t, 2H), 2.70-2.97 (m, 7H), 3.44, 3.53
30 (t, t, 2H), 3.84-3.92 (m, 9H), 5.49 (s, br, 2H), 6.61-6.82 (m, 3H), 6.92 (t, 2H), 7.05 (d, 1H), 7.15 (d, 1H), 7.38 (t, 1H), 7.55 (t, 1H), 7.74-7.77 (m, 1H) and 8.03 (d, 1H).

c) 2-[(4-{3-[[2-(3,4-Dimethoxyphenyl)ethyl](methyl)amino]-3-oxopropyl}phenoxy)-methyl]benzoic acid

Lithium hydroxide (12 mg, 0.488 mmol) in water (1 ml) was added to methyl 2-[(4-{3-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-3-oxopropyl}phenoxy)methyl]benzoate (120 mg, 0.244 mmol) dissolved in THF (2 ml). The mixture was then irradiated in a microwave oven (Smith Synthesizer) at 150 °C for 7 minutes and then evaporated to remove THF. The residue was acidified with 1% hydrochloric acid, pH~4, and extracted with ethyl acetate (x2). The organic extracts were combined and washed with brine and dried with magnesium sulphate and then evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6ml) using DCM, then MeOH/DCM (1:99) as eluant gave 102 mg the desired product, yield 87.5%.

¹H NMR (rotamers, 500 MHz, CDCl₃): δ 2.40, 2.64 (t, t, 2H), 2.73-3.01 (m, 7H), 3.47, 3.63 (t, t, 2H), 3.85- 3.88 (m, 6H), 5.56, 5.57 (s, s, 2H), 6.63-6.83 (m, 3H), 6.93-6.97 (m, 2H), 7.07 (d, 1H), 7.17 (d, 1H), 7.41 (t, 1H), 7.57-7.61 (m, 1H), 7.81 (t, 1H) and 8.18 (d, 1H).

Example 6

a) Methyl 2-[(4-{2-[(*tert*-butoxycarbonyl)amino]ethyl}phenoxy)methyl]benzoate

tert-Butyl 2-(4-hydroxyphenyl)ethylcarbamate (3.534 g, 14.9 mmol), 2-bromomethylbenzoic acid methyl ester (3.582 g, 15.6 mmol) and potassium carbonate, anhydrous (3.087 g, 22.3 mmol) were mixed in acetonitrile (50 ml). The mixture was heated to reflux overnight and then evaporated to dry. Water and ethyl acetate were added and the two phases were separated. The organic phase was dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 20g/70ml) using DCM and then MeOH/DCM (1:99) as eluant gave 5.427 g the desired product, yield 94.5%.

¹H NMR (500 MHz, CDCl₃): δ 1.44 (s, 9H), 2.72 (t, 2H), 3.30-3.35 (m, 2H), 3.86 (s, 3H), 4.87 (s, br, 1H), 5.46 (s, 2H), 6.92 (d, 2H), 7.09 (d, 2H), 7.33 (t, 1H), 7.51 (t, 1H), 7.74 (d, 1H) and 8.00 (d, 1H).

b) Methyl 2-[[4-(2-aminoethyl)phenoxy]methyl]benzoate hydrochloride

Methyl 2-[[4-(2-[(*tert*-butoxycarbonyl)amino]ethyl)phenoxy]methyl]benzoate (5.1 g, 13.2 mmol) was dissolved in ethyl acetate (50 ml) and it was cooled in an ice-bath.

5 Hydrochloric acid (4M in dioxane, 30 ml, 120 mmol) was added. The cooling bath was removed after 30 minutes. The mixture was stirred for 3 hours more and white precipitates fell out during the time. The reaction mixture was evaporated to dry. Ethyl acetate (20 ml) was added into the residue. It was then filtered. White solid product (3.785 g) was obtained, yield 89%.

10 ¹H NMR (500 MHz, CDCl₃): δ 3.06 (t, 2H), 3.23 (t, 2H), 3.90 (s, 3H), 5.45 (s, 2H), 6.93 (d, 2H), 7.18 (d, 2H), 7.37 (t, 1H), 7.55 (t, 1H), 7.73 (d, 1H), 8.02 (d, 1H) and 8.35 (s, br, 2H).

c) Methyl 2-[[4-{2-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)carbonyl]amino]ethyl}phenoxy]methyl]benzoate

4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid (50 mg, 0.174 mmol) and methyl 2-[[4-(2-aminoethyl)phenoxy]methyl]benzoate hydrochloride (59 mg, 0.183 mmol) were mixed in DMF (4 ml) and the mixture was then cooled in an ice-bath.

20 TBTU (59 mg, 0.183 mmol) was added and followed by DIPEA (47.2 mg, 0.366 mmol). The mixture was stirred at room temperature overnight. Ethyl acetate and sodium hydrogencarbonate aqueous solution (sat.) were added. The two phases were separated. The organic phase was washed with water and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6ml) using DCM and then

25 MeOH/DCM (0.5:99.5) as eluant gave 59 mg the desired product, white solid, yield 61%. ¹H NMR (400 MHz, CDCl₃): δ 2.62 (s, 3H), 2.87 (t, 2H), 3.67 (dt, 2H), 3.89 (s, 3H), 5.49 (s, 2H), 5.86 (t, 1H), 6.97 (d, 2H), 7.15 (d, 2H), 7.36 (t, 1H), 7.54 (t, 1H), 7.67 (d, 2H), 7.74 (d, 2H) and 7.99-8.03 (m, 3H).

d) 2-[(4-{2-[(4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)carbonyl]amino}ethyl)phenoxy)methyl]benzoic acid

Lithium hydroxide (4 mg, 0.166 mmol) in water (1 ml) was added into methyl 2-[(4-{2-
 5 [(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)carbonyl]amino}ethyl)-
 phenoxy)methyl]benzoate (46 mg, 0.083 mmol) dissolved in THF (2 ml). The mixture was
 then irradiated in a microwave oven (Smith Synthesizer) at 150 °C for 7 minutes and then
 evaporated to remove THF. The residue was acidified with 1% hydrochloric acid, pH~4,
 and extracted with ethyl acetate (x2). The organic extracts were combined and dried with
 10 magnesium sulphate and then evaporated. Chromatography of the residue on a column
 (ISOLUTE® SI, 2g/6ml) using DCM, then MeOH/DCM (1:99) as eluant gave 38 mg the
 desired product, yield 85%.

¹H NMR (400 MHz, THF-d₈): δ 2.65 (s, 3H), 2.85 (t, 2H), 3.54 (dt, 2H), 5.52 (s, 2H), 6.94
 (d, 2H), 7.17 (d, 2H), 7.36 (t, 1H), 7.41 (t, 1H), 7.53 (t, 1H), 7.75-7.79 (m, 3H), 8.06 (d,
 15 1H) and 8.14 (d, 2H).

Example 7

a) Methyl 2-[(4-{2-[(2,4-difluorophenyl)amino]carbonyl}amino)ethyl]phenoxy)-
 methyl]benzoate

20 2,4-Difluorophenyl isocyanate (26.5 mg, 0.171 mmol) and methyl 2-[(4-(2-
 aminoethyl)phenoxy)methyl]benzoate hydrochloride (55 mg, 0.171 mmol) were mixed in
 DCM (4 ml). PS-DIEA (3.66mmol/g, 140 mg, 0.512 mmol) was added. The mixture was
 shaken at room temperature overnight. White precipitates were falling out. The mixture
 25 was evaporated to dry. The residue (with addition of DCM, a suspension) was loaded on a
 column (ISOLUTE® SI, 2g/6ml) and eluted with DCM and then MeOH/DCM (1:99).

White solid product 51 mg was obtained, yield 68%.

¹H NMR (400 MHz, DMSO-d₆): δ 2.65 (t, 2H), 3.26-3.31 (m, 2H), 3.79 (s, 3H), 5.36 (s,
 2H), 6.49 (t, 1H), 6.88-6.97 (m, 3H), 7.12-7.22 (m, 3H), 7.44 (t, 1H), 7.58-7.65 (m, 2H),
 30 7.88 (d, 1H), 8.01-8.07 (m, 1H) and 8.23 (s, br, 1H).

b) 2-({4-[2-({[(2,4-Difluorophenyl)amino]carbonyl}amino)ethyl]phenoxy}methyl)benzoic acid

Lithium hydroxide (3.7 mg, 0.154 mmol) in water (1 ml) was added into methyl 2-({4-[2-
5 ({[(2,4-difluorophenyl)amino]carbonyl}amino)ethyl]phenoxy}methyl)benzoate (34 mg,
0.077 mmol) dissolved in THF (2 ml). The mixture was then irradiated in a microwave
oven (Smith Synthesizer) at 150 °C for 7 minutes and then evaporated to remove THF. The
residue was acidified with 1% hydrochloric acid, pH~4, and extracted with ethyl acetate
(x2). The organic extracts were combined and dried with magnesium sulphate and then
10 evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 1g/6ml) using
MeOH/DCM (1:99, 2:98, 4:96 and then 10: 90) as eluant gave 18 mg the desired product,
yield 55%.

¹H NMR (400 MHz, THF-d₈): δ 2.76 (t, 2H), 3.39-3.44 (m, 2H), 5.51 (s, 2H), 6.40 (t, 1H),
6.79-6.94 (m, 4H), 7.16 (d, 2H), 7.35 (t, 1H), 7.53 (t, 1H), 7.76 (d, 1H), 7.93 (s, br, 1H),
15 8.06 (d, 1H) and 8.29-8.35 (m, 1H).

Example 8

a) Methyl 2-[(4-{2-[(2-methyl-5-phenyl-3-furoyl)amino]ethyl}phenoxy)methyl]benzoate

2-Methyl-5-phenylfuran-3-carbonyl chloride (36.4 mg, 0.165 mmol) and methyl 2-[(4-(2-
20 aminoethyl)phenoxy)methyl]benzoate hydrochloride (53 mg, 0.165 mmol) were mixed in
DCM (4 ml). PS-DIEA (3.66 mmol/g, 135 mg, 0.494 mmol) was added. The mixture was
shaken at room temperature overnight. LC-MS showed there was only a trace amount of
desired product and a big peak of 2-methyl-5-phenyl-3-furoic acid. TBTU (55 mg, 0.17
25 mmol) was added. The mixture was shaken for 2 hours and filtered. The filtrate was
evaporated to dryness. Chromatography of the residue on a column (ISOLUTE® SI,
2g/6ml) using DCM and then MeOH/DCM (0.5:99.5) as eluant gave 34 mg the desired
product, yield 44%.

¹H NMR (500 MHz, CDCl₃): δ 2.61 (s, 3H), 2.85 (t, 2H), 3.60-3.66 (m, 2H), 3.89 (s, 3H),
30 5.49 (s, 2H), 5.82 (t, 1H), 6.55 (s, 1H), 6.96 (d, 2H), 7.15 (d, 2H), 7.25 (t, 1H), 7.36 (t, 3H),
7.52-7.63 (m, 3H), 7.75 (d, 1H) and 8.02 (d, 1H).

b) 2-[(4-{2-[(2-Methyl-5-phenyl-3-furoyl)amino]ethyl}phenoxy)methyl]benzoic acid

Lithium hydroxide (3.3 mg, 0.136 mmol) in water (1 ml) was added into methyl 2-[(4-{2-[(2-methyl-5-phenyl-3-furoyl)amino]ethyl}phenoxy)methyl]benzoate

5 (32 mg, 0.068 mmol) dissolved in THF(2 ml). The mixture was then irradiated in a microwave oven (Smith Synthesizer) at 150 °C for 7 minutes and then evaporated to remove THF. The residue was acidified with 1% hydrochloric acid, pH~4, and extracted with ethyl acetate (x2). The organic extracts were combined and washed with brine and dried with magnesium sulphate and then evaporated. Chromatography of the residue on a
10 column (ISOLUTE® SI, 2g/6ml) using DCM, then MeOH/DCM (1:99 and 2:98) as eluant gave 22 mg the desired product, yield 71%.

¹H NMR (400 MHz, CDCl₃): δ 2.60 (s, 3H), 2.84 (t, 2H), 3.60-3.65 (m, 2H), 5.51 (s, 2H), 5.90 (t, 1H), 6.56 (s, 1H), 6.94 (d, 2H), 7.13 (d, 2H), 7.23 (t, 1H), 7.32-7.40 (m, 3H), 7.55-7.60 (m, 3H), 7.77 (d, 1H) and 8.13 (d, 1H).

15

Example 9

a) Methyl 2-[(4-{2-[(benzylsulfonyl)amino]ethyl}phenoxy)methyl]benzoate

Alpha-toluenesulfonyl chloride (38 mg, 0.199 mmol) and methyl 2-[(4-(2-
20 aminoethyl)phenoxy)methyl]benzoate hydrochloride (64 mg, 0.199 mmol) were mixed in DCM (3 ml). PS-DIEA (3.66 mmol/g, 272 mg, 0.997 mmol) was added. The mixture was shaken at room temperature over a weekend. It was then loaded on a column (ISOLUTE® SI, 1g/6ml) and eluted with DCM. The product fractions were combined and evaporated. Oil product (17 mg) was obtained, yield 19%.

25 ¹H NMR (500 MHz, CDCl₃): δ 2.74 (t, 2H), 3.19-3.23 (m, 2H), 3.92 (s, 3H), 4.12 (t, 1H), 4.21 (s, 2H), 5.50 (s, 2H), 6.94 (d, 2H), 7.07 (d, 2H), 7.32-7.42 (m, 6H), 7.57 (t, 1H), 7.75 (d, 1H) and 8.05 (d, 1H).

b) 2-[(4-{2-[(Benzylsulfonyl)amino]ethyl}phenoxy)methyl]benzoic acid

30

Lithium hydroxide (2 mg, 0.077 mmol) in water (0.5 ml) was added into methyl 2-[(4-{2-[(benzylsulfonyl)amino]ethyl}phenoxy)methyl]benzoate (17 mg, 0.038 mmol) dissolved in

THF (1 ml). The mixture was then irradiated in a microwave oven (Smith Synthesizer) at 150 °C for 7 minutes and then evaporated to remove THF. The residue was acidified with 1% hydrochloric acid, pH~4, and extracted with ethyl acetate (x2). The organic extracts were combined and dried with MgSO₄ and then evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 500 mg/3 ml) using DCM, then MeOH/DCM (0.5:99.5) as eluant gave 10 mg the desired product, yield 61%.

¹H NMR (400 MHz, CDCl₃): δ 2.70 (t, 2H), 3.16-3.21 (m, 2H), 4.18 (s, 2H), 4.29 (t, 1H), 5.48 (s, 2H), 6.91 (d, 2H), 7.05 (d, 2H), 7.29-7.35 (m, 5H), 7.41 (t, 1H), 7.59 (t, 1H), 7.76 (d, 1H) and 8.14 (d, 1H).

Example 10

a) *N*-Benzyl-2-(3-fluoro-4-hydroxyphenyl)-*N*-hexylacetamide

3-Fluoro-4-hydroxyphenylacetic acid (170 mg, 0.999 mmol) dissolved in DMF (3 ml) was cooled in an ice-bath. *N*-Hexylbenzylamine (201 mg, 1.049 mmol) was added and then TBTU (337 mg, 1.049 mmol) followed by DIPEA (407 mg, 3.147 mmol). The mixture was stirred at room temperature overnight and evaporated. Sodium hydrogencarbonate aqueous solution (sat.) was added into the residue. The mixture was then extracted with ethyl acetate (x2). The extracts were combined and washed with water and brine and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 5g/15 ml) using DCM and then MeOH/DCM (1:99) as eluant gave 265 mg the desired product, yield 77%.

¹H NMR (rotamers, 400 MHz, CDCl₃): δ 0.83-0.89 (m, 3H), 1.22-1.29 (m, 6H), 1.48-1.58 (m, 2H), 3.21, 3.40 (t, t, 2H), 3.58, 3.68 (s, s, 2H), 4.54, 4.63 (s, s, 2H), 6.72-6.97 (m, 3H), 7.15 (d, 1H), 7.21-7.32 (m, 3H) and 7.35-7.39 (m, 1H).

b) Methyl 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl})-2-fluorophenoxy)methyl]benzoate

N-benzyl-2-(3-fluoro-4-hydroxyphenyl)-*N*-hexylacetamide (142 mg, 0.414 mmol), 2-bromomethylbenzoic acid methyl ester (99.4 mg, 0.434 mmol) and potassium carbonate anhydrous (86 mg, 0.620 mmol) were mixed in acetonitrile (5 ml). The mixture was heated to reflux overnight and then evaporated to dry. Ethyl acetate and water were added and the

two phases were separated. The organic phase was washed with brine and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6 ml) using DCM, MeOH/DCM (0.5:99.5) as eluant gave 144 mg the desired product, yield 71%.

- 5 ¹H NMR (rotamers, 400 MHz, CDCl₃): δ 0.83-0.89 (m, 3H), 1.20-1.29 (m, 6H), 1.45-1.58 (m, 2H), 3.18, 3.37 (t, t, 2H), 3.58, 3.69 (s, s, 2H), 3.90 (s, 3H), 4.50, 4.60 (s, s, 2H), 5.53, 5.55 (s, s, 2H), 6.82-7.39 (m, 9H), 7.56 (t, 1H), 7.78-7.82 (m, 1H) and 8.02 (d, 1H).

c) 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-fluorophenoxy)methyl]benzoic acid

10

Methyl 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-fluorophenoxy)methyl]benzoate (109 mg, 0.222 mmol) was dissolved in THF (2 ml). Lithium hydroxide (10.6 mg, 0.444 mmol) solved in water (1 ml) was added. The mixture was put in a microwave oven (Smith Synthesizer) at 150 °C for 7 minutes. It was then acidified with 1% hydrochloric acid, pH~3, and extracted with ethyl acetate. The organic extract was washed with brine and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g / 6 ml) using DCM and then MeOH/DCM (0.5: 99.5, then 1:99) as eluant gave 89 mg the desired product, yield 84%.

15

- ¹H NMR (rotamers, 300 MHz, CDCl₃): δ 0.84-0.92 (m, 3H), 1.26 (s, br, 6H), 1.48-1.60 (m, 2H), 3.21, 3.41 (t, t, 2H), 3.65, 3.75 (s, s, 2H), 4.55, 4.66 (s, s, 2H), 5.60 (s, 2H), 6.84-7.43 (m, 9H), 7.62 (t, 1H), 7.85 (d, 1H) and 8.16

20

Example 11

a) N-Benzyl-N-hexyl-2-(4-hydroxy-3-methoxyphenyl)acetamide

25

Homovanillic acid (182 mg, 0.999 mmol) dissolved in DMF (3 ml) was cooled in an ice-bath. N-Hexylbenzylamine (201 mg, 1.049 mmol) was added and then TBTU (337 mg, 1.049 mmol) followed by DIPEA (407 mg, 3.147 mmol). The mixture was stirred at room temperature overnight and evaporated. Sodium hydrogencarbonate aqueous solution (sat.) was added into the residue. The mixture was then extracted with ethyl acetate (x2). The extracts were combined and washed with water and brine and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 5g/15 ml)

30

using DCM and then MeOH/DCM (1:99) as eluant gave 264 mg the desired product, yield 74%.

¹H NMR (rotamers, 400 MHz, CDCl₃): δ 0.83-0.89 (m, 3H), 1.20-1.29 (m, 6H), 1.44-1.56 (m, 2H), 3.18, 3.37 (t, t, 2H), 3.60, 3.71 (s, s, 2H), 3.81 (s, br, 3H), 4.50, 4.61 (s, s, 2H),
5 5.98 (s, br, 1H), 6.62-6.85 (m, 3H) and 7.11-7.36 (m, 5H).

b) Methyl 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-methoxyphenoxy)methyl]benzoate

10 *N*-Benzyl-*N*-hexyl-2-(4-hydroxy-3-methoxyphenyl)acetamide (84 mg, 0.236 mmol), 2-bromomethylbenzoic acid methyl ester (57 mg, 0.248 mmol) and potassium carbonate anhydrous (49 mg, 0.355 mmol) were mixed in acetonitrile (5 ml). The mixture was heated to reflux overnight and then evaporated to dry. Ethyl acetate and water were added and the two phases were separated. The organic phase was washed with brine and dried
15 (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6 ml) using DCM, MeOH/DCM (0.5:99.5) as eluant gave 102 mg the desired product yield 86%.

¹H NMR (rotamers, 400 MHz, CDCl₃): δ 0.82-0.88 (m, 3H), 1.18-1.28 (m, 6H), 1.43-1.55 (m, 2H), 3.17, 3.35 (t, t, 2H), 3.61, 3.71 (s, s, 2H), 3.86 (s, 3H), 3.88 (s, 3H), 4.48, 4.60 (s,
20 s, 2H), 5.55, 5.56 (s, s, 2H), 6.61-7.35 (m, 9H), 7.52 (t, 1H), 7.78 (d, 1H) and 8.01 (d, 1H).

c) 2-[(4-{2-[Benzyl(hexyl)amino]-2-oxoethyl}-2-methoxyphenoxy)methyl]benzoic acid

Methyl 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-methoxyphenoxy)methyl]benzoate (98 mg, 0.195 mmol) was dissolved in THF (2 ml). Lithium hydroxide (9.3 mg, 0.389 mmol) solved in water (1 ml) was added. The mixture was put in a microwave oven (Smith
5 Synthesizer) at 150 °C for 7 minutes. It was then acidified with 1% hydrochloric acid, pH~3, and extracted with ethyl acetate. The organic extract was washed with brine and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g / 6 ml) using DCM and then MeOH/DCM (0.5: 99.5, then 1:99) as eluant gave 43 mg the desired product, yield 45%.
10 ¹H NMR (rotamers, 400 MHz, CDCl₃): δ 0.82-0.88 (m, 3H), 1.18-1.28 (m, 6H), 1.44-1.57 (m, 2H), 3.18, 3.37 (t, t, 2H), 3.64, 3.74 (s, s, 2H), 3.86 (s, 3H), 4.50, 4.62 (s, s, 2H), 5.57, 5.58 (s, s, 2H), 6.63-7.39 (m, 9H), 7.56 (t, 1H), 7.80 (d, 1H) and 8.12 (d, 1H).

Example 12

15 a) 4-[3-(3,4-Dihydroisoquinolin-2(1H)-yl)-3-oxopropyl]phenol

3-(4-Hydroxyphenyl)propionic acid (202 mg, 1.216 mmol) in DMF (3 ml) was cooled in an ice-bath. 1,2,3,4-Tetrahydroisoquinoline (170 mg, 1.276 mmol) was added and then TBTU (410 mg, 1.276 mmol) followed by DIPEA (330 mg, 2.553 mmol). The mixture
20 was stirred at room temperature overnight. Sodium hydrogencarbonate aqueous solution (sat.) was added. The mixture was extracted with ethyl acetate (x2). The extracts were combined and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6 ml) using DCM and then MeOH/DCM (1:99) as eluant gave 303 mg the desired product, yield 89%.
25 ¹H NMR (rotamers, 400 MHz, CDCl₃): δ 2.72-2.77 (m, 2H), 2.83-2.90 (m, 2H), 2.95-3.01 (m, 2H), 3.63, 3.88 (t, t, 2H), 4.57, 4.79 (s, s, 2H), 6.85-6.90 (m, 2H) and 7.07-7.26 (m, 6H).

b) Methyl 2-({4-[3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl]phenoxy}methyl)-benzoate
30

4-[3-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-oxopropyl]phenol (155 mg, 0.551 mmol) was dissolved in acetonitrile (10 ml). 2-Bromomethylbenzoic acid methyl ester (126 mg, 0.551 mmol) was added followed by potassium carbonate anhydrous (114 mg, 0.826 mmol). The mixture was heated to reflux overnight and then evaporated to dry. Water and ethyl acetate were added and two phases were separated. The organic phase was dried (magnesium sulphate) and evaporated. Column chromatography of the residue on silica gel using ethyl acetate/heptane (40:60) as eluant gave 135 mg the desired product, yield 57%.

¹H NMR (rotamers, 500 MHz, CDCl₃): δ 2.69-2.74 (m, 2H), 2.82-2.87 (m, 2H), 2.95-3.01 (m, 2H), 3.62, 3.85 (t, t, 2H), 3.93 (s, 3H), 4.52, 4.73 (s, s, 2H), 5.48, 5.50 (s, s, 2H), 6.91-6.95 (m, 2H), 7.03-7.24 (m, 6H), 7.39 (t, 1H), 7.57 (t, 1H), 7.77 (d, 1H) and 8.05 (d, 1H).

c) 2-({4-[3-(3,4-Dihydroisoquinolin-2(1*H*)-yl)-3-oxopropyl]phenoxy}methyl)benzoic acid

Lithium hydroxide (14.4 mg, 0.6 mmol) dissolved in water (1 ml) was added into methyl 2-({4-[3-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3-oxopropyl]phenoxy}methyl)benzoate (129 mg, 0.3 mmol) in THF (2 ml). The mixture was put in a microwave oven (Smith Synthesizer) and irradiated at 150 °C for 7 minutes and then evaporated to remove THF. The residue was acidified with 1% hydrochloric acid, pH~5, and extracted with ethyl acetate (x2). The extracts were combined and dried (magnesium sulphate) and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6ml) using DCM, MeOH/DCM (1:99) as eluant gave 111 mg the desired product yield 89%.

¹H NMR (rotamers, 400 MHz, CDCl₃): δ 2.70-2.73 (m, 2H), 2.79-2.83 (m, 2H), 2.92-3.00 (m, 2H), 3.58, 3.84 (t, t, 2H), 4.50, 4.76 (s, s, 2H), 5.50, 5.53 (s, s, 2H), 6.87-6.93 (m, 2H), 6.99-7.22 (m, 6H), 7.39 (t, 1H), 7.57 (t, 1H), 7.78 (d, 1H) and 8.16 (d, 1H).

Example 13

a) 4-(2-Hydroxyethyl)phenol (2 g, 14.48 mmol) and methyl 2-(bromomethyl)benzoate (3.48 g, 15.20 mmol) were dissolved in acetonitrile (20 ml). Potassium carbonate anhydrous (4.0 g, 28.95 mmol) was added. After stirring at 60° C for three hours PS-trisamine was added (0.2 eq) and the mixture was stirred overnight. The PS-trisamine was filtered off and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer was washed with 3 portions of water (3 X 10 ml). The organic phase

was dried (MgSO₄) and the solvent was removed by evaporation to give 3.732 g of methyl 2-[[4-(2-hydroxyethyl)phenoxy]methyl]benzoate (yield 90%).

¹HNMR (300 MHz, CDCl₃): δ 2.37 (bs, 1H), 2.8 (t, 2H), 3.8 (bm, 2H), 3.9 (s, 3H), 5.5 (s, 2H), 6.95 (d, 2H), 7.15 (d, 2H), 7.25 (t, 1H), 7.55 (t, 1H), 7.75 (d, 1H), 8.05 (d, 1H)

b) Methyl 2-[[4-(2-hydroxyethyl)phenoxy]methyl]benzoate (1.2 g, 4.19 mmol) was dissolved in dichloromethane (20 ml) and the solution was cooled to -20° C. Triethylamine (0.64 g, 6.29 mmol) was added dropwise, and then methylsulfonyl chloride (0.53 g, 4.61 mmol) was added dropwise. The ice bath was removed and the mixture was stirred at room temperature for one hour. Diethyl ether (5ml) was added and the precipitate was filtered off. The organic phase was washed with 2 portions of brine, dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (starting with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). This gave 0.703 g of methyl 2-[[4-{2-[(methylsulfonyl)oxy]ethyl}phenoxy)-methyl]benzoate (yield 46%).

¹HNMR (300 MHz, CDCl₃): δ 2.8 (s, 3H), 2.95 (t, 2H), 3.85 (s, 3H), 4.35 (t, 2H), 5.45 (s, 2H), 6.9 (d, 2H), 7.15 (d, 2H), 7.35 (t, 1H), 7.5 (t, 1H), 7.7 (d, 1H), 7.98 (d, 1H)

c) Methyl 2-[[4-{2-[(methylsulfonyl)oxy]ethyl}phenoxy)methyl]benzoate (0.2 g, 0.55 mmol) and 4-(1*H*-imidazol-1-yl)phenol (0.11 g, 0.66 mmol) was dissolved in acetonitrile (10 ml) and potassium carbonate (0.09 g, 0.66 mmol) was added. The mixture was stirred over night at 75° C. Remove the acetonitrile by evaporation, dilute with EtOAc (10 ml) and wash the organic phase with Brine three times, dry (MgSO₄) and evaporate. This gave 0.268 g of methyl 2-[[4-{2-[4-(1*H*-imidazol-1-yl)phenoxy]ethyl}phenoxy)methyl]benzoate (yield 90%).

30

¹HNMR (300 MHz, CDCl₃): δ 3.05 (t, 2H), 3.9 (s, 3H), 4.05-4.2 (bm, 2H), 5.55 (s, 2H), 6.9-7.0 (bm, 4H), 7.1-7.4 (bm, 7H), 7.52 (t, 2H), 7.75 (m, 2H), 7.98 (d, 1H)

d) Methyl 2-[(4-{2-[4-(1*H*-imidazol-1-yl)phenoxy]ethyl}phenoxy)methyl]benzoate (0.12 g, 0.28 mmol) was dissolved in a mixture of THF/water (7/1, 5 ml) and LiOH (0.03 g, 1.13 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). Workup by addition of HCl (1 ml, 1M), extract the product by adding two portions of EtOAc (5 ml). The pooled organic phases were dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (starting with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Evaporation gave 6 mg of 2-[(4-{2-[4-(1*H*-imidazol-1-yl)phenoxy]ethyl}-phenoxy)methyl]benzoic acid (yield 4.7%).

¹HNMR (500 MHz, CDCl₃): δ 3.05 (t, 2H), 4.18 (t, 2H), 5.55 (s, 2H), 6.95 (d, 2H), 7.05 (m, 3H), 7.25 (d, 2H), 7.3-7.45 (bm, 4H), 7.55 (t, 1H), 7.78 (d, 1H), 7.85 (s, 1H), 8.07 (d, 1H).

Example 14

a) 4-(2-Hydroxyethyl)phenol (2 g, 14.48 mmol) and methyl 2-(bromomethyl)benzoate (3.48 g, 15.20 mmol) was dissolved in acetonitrile (20 ml). Potassium carbonate anhydrous (4.0 g, 28.95 mmol) was added. After stirring at 60°C for three hours PS-trisamine was added (0.2 eq) and was stirred overnight. The PS-trisamine was filtered off and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer was washed with 3 portions of water (3 X 10 ml). The organic phase was dried (MgSO₄) and the solvent was removed by evaporation to give 3.732 g of methyl 2-[(4-(2-hydroxyethyl)phenoxy)methyl]benzoate (yield 90%).

¹HNMR (300 MHz, CDCl₃): δ 2.37 (bs, 1H), 2.8 (t, 2H), 3.8 (bm, 2H), 3.9 (s, 3H), 5.5 (s, 2H), 6.95 (d, 2H), 7.15 (d, 2H), 7.25 (t, 1H), 7.55 (t, 1H), 7.75 (d, 1H), 8.05 (d, 1H)

b) Methyl 2-[[4-(2-hydroxyethyl)phenoxy]methyl]benzoate (1g, 3.49 mmol), 4-(benzyloxy)phenol (0.7 g, 3.49 mmol) and triphenylphosphine (1.01 g, 3.84 mmol) was added to a dry round bottomed flask fitted with a septum. N₂ was flushed through the flask for 5 minutes followed by the addition of dry toluene (30 ml) and diisopropylazodicarboxylate (0.78 g, 3.84 mmol). The reaction mixture was stirred at 55° C overnight. The solvent was removed by evaporation and the crude material was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). After removing the solvent by evaporation, 0.7g of methyl 2-[(4-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate was isolated (yield 42.8%).

¹HNMR (300 MHz, CDCl₃): δ 3.05 (t, 2H), 3.95 (s, 3H), 4.07 (t, 2H), 5.03 (s, 2H), 5.55 (s, 2H), 6.85 (d, 2H), 6.95 (d, 2H), 6.98 (d, 2H), 7.23 (d, 2H), 7.3-7.5 (bm, 6H), 7.6 (t, 1H), 7.8 (d, 1H), 8.07 (d, 1H).

c) Methyl 2-[(4-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate (0.80 g 1.71 mmol), borontrifluoride etherate (2.42 g, 17.09 mmol) and dimethyl sulfide (1.27 g, 20.51 mmol) were dissolved in dichloromethane (25 ml). The mixture was stirred for 6 hours at room temperature. EtOAc (20 ml) was added and the mixture was washed with three portions of water, the organic layer dried (MgSO₄) and the solvent removed by evaporation.

¹HNMR (300 MHz, CDCl₃): δ 3.0 (t, 2H), 3.9 (s, 3H), 4.1 (t, 2), 5.5 (s, 2H), 5.55 (s, 2H), 6.8 (bm, 4H), 7.0 (d, 2H), 7.2 (d, 2H), 7.4 (t, 1H), 7.55 (t, 1H), 7.8 (d, 1H), 8.05 (d,

d) Methyl 2-[(4-{2-(4-hydroxyphenoxy)ethyl}phenoxy)methyl]benzoate (0.547 g, 1.45 mmol) was dissolved in dichloromethane (10 ml) and the solution was cooled to -20°C. Triethylamine (0.22 g, 2.17 mmol) was added dropwise followed by the dropwise addition

of methylsulfonyl chloride (0.18 g, 1.59 mmol). The ice bath was removed and the mixture was stirred overnight at room temperature. Excess of triethylamine was removed by addition of diethyl ether (5 ml) and filtering off the precipitate. The organic phase was washed with three portions of brine (10 ml) and dried (MgSO_4). The solvent was removed by evaporation, the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO_4). Removing the solvent by evaporation gave 0.317g of methyl 2-{[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenoxy]methyl}benzoate (yield 48%).

^1H NMR (500 MHz, CDCl_3): δ 3.07 (t, 2H), 3.15 (s, 3H), 3.95 (s, 3H), 4.17 (t, 2H), 5.55 (s, 2H), 6.95 (d, 2H), 7.0 (d, 2H), 7.23 (m, 4H), 7.42 (t, 1H), 7.6 (t, 1H), 7.8 (d, 1H), 8.08 (d, 1H).

e) Methyl 2-{[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenoxy]methyl}benzoate (0.18 g, 0.38 mmol) was dissolved in a mixture of tetrahydrofuran and water 7:1 (5 ml). The reaction was performed in a single mode microwave oven (150° C in 7 minutes). The mixture was diluted with HCl (2 ml, 1 M) and the organic phase was isolated. The crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO_4). Removing the solvent by evaporation gave 13 mg of 2-{[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenoxy]methyl}benzoic acid (yield 7.7%).

^1H NMR (300 MHz, CDCl_3): δ 3.07 (t, 2H), 3.15 (s, 3H), 4.17 (t, 2H), 5.6 (s, 2H), 6.95 (d, 2H), 7.0 (d, 2H), 7.23 (m, 4H), 7.42 (t, 1H), 7.65 (t, 1H), 7.82 (d, 1H), 8.2 (d, 1H).

Example 15

a) 3-(2-Hydroxyethyl)phenol (1.0 g, 7.24 mmol) and methyl 2-(bromomethyl)benzoate
5 (1.74 g, 7.6 mmol) were dissolved in acetonitrile (10 ml). Potassium carbonate anhydrous
(2.0 g, 14.48 mmol) was added. After stirring at 60°C for three hours PS-trisamine was
added (0.3 eq) and was stirred overnight. The PS-trisamine was filtered off and the
acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer
was washed with 3 portions of water (3 X 10 ml). The organic phase was dried (MgSO₄)
10 and the solvent was removed by evaporation to give 1.99 g of methyl 2-[[3-(2-
hydroxyethyl)phenoxy]methyl]benzoate (yield 90%).

¹HNMR (300 MHz, CDCl₃): δ 2.95 (t, 2H), 3.45 (s, 1H), 3.9 – 4.0 (bm, 5H), 5.58 (s, 2H),
6.95 (m, 2H), 7.05 (s, 1H), 7.3 (t, 1H), 7.45 (t, 1H), 7.6 (t, 1H), 7.85 (d, 1H), 8.05 (d, 1H)

15

b) Methyl 2-[[3-(2-hydroxyethyl)phenoxy]methyl]benzoate (0.5g, 1.75 mmol), 4-
(benzyloxy)phenol (0.35 g, 1.75 mmol) and triphenylphosphine (0.5 g, 1.92 mmol) were
added to a dry roundbottomed flask and fitted with a septum. Dry toluene (10 ml) was
added and N₂ was flushed through the mixture for 5 minutes. Diisopropyl (*E*)-diazene-1,2-
20 dicarboxylate (0.39 g, 1.92 mmol) was added dropwise and the solution was stirred at
room temperature. After three hour, another equivalent of reagents was added and stirred
for one hour. After removing the solvent by evaporation the crude was purified by
preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile
concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90
25 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40
ml/min). The product containing fractions was pooled and the acetonitrile was removed by
evaporation. EtOAc (10 ml) was added and the organic phase was washed with two
portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 0.319 g
methyl 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate (yield 39%).

30

¹HNMR (300 MHz, CDCl₃): δ 3.15 (t, 2H), 3.95 (s, 3H), 4.2 (t, 2H), 5.07 (s, 2H), 5.6 (s,
2H), 6.9 – 7.1 (bm, 7H), 7.3 – 7.55 (bm, 7H), 7.6 (t, 1H), 7.85 (d, 1H), 8.05 (d, 1H)

- c) Methyl 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate (20 mg, 0.043 mmol) was dissolved in a mixture of THF/H₂O (7/1, 3 ml) and LiOH (4.1 mg, 0.17 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C).
- 5 The mixture was acidified (HCl, 1 ml, 1M) and the water phase washed with two portions of EtOAc (3 X 5 ml). After removing the solvent by evaporation the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40
- 10 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 19 mg of 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoic acid (yield 98 %).
- ¹HNMR (300 MHz, CDCl₃): δ 3.1 (t, 2H), 4.15 (t, 2H), 5.03 (s, 2H), 5.57 (s, 2H), 6.8 – 7.0 (bm, 7H), 7.2 – 7.5 (bm, 7H), 7.6 (t, 1H), 7.85 (d, 1H), 8.15 (d, 1H)
- 15

Example 16

- a) 3-(2-Hydroxyethyl)phenol (1.0 g, 7.24 mmol) and methyl 2-(bromomethyl)benzoate
- 20 (1.74 g, 7.6 mmol) were dissolved in acetonitrile (10 ml). Potassium carbonate anhydrous (2.0 g, 14.48 mmol) was added. After stirring at 60°C for three hours PS-trisamine was added (0.3 eq) and was stirred overnight. The PS-trisamine was filtered off and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer was washed with 3 portions of water (3 X 10 ml). The organic phase was dried (MgSO₄)
- 25 and the solvent was removed by evaporation to give 1.99 g of methyl 2-[(3-(2-hydroxyethyl)phenoxy)methyl]benzoate (yield 90%).

¹HNMR (300 MHz, CDCl₃): δ 2.95 (t, 2H), 3.45 (s, 1H), 3.9 – 4.0 (bm, 5H), 5.58 (s, 2H), 6.95 (m, 2H), 7.05 (s, 1H), 7.3 (t, 1H), 7.45 (t, 1H), 7.6 (t, 1H), 7.85 (d, 1H), 8.05 (d, 1H)

30

- b) Methyl 2-[(3-(2-hydroxyethyl)phenoxy)methyl]benzoate (0.5g, 1.75 mmol), 4-(benzyloxy)phenol (0.35 g, 1.75 mmol) and triphenylphosphine (0.5 g, 1.92 mmol) was

added to a dry round bottomed flask and fitted with septum. Dry toluene (10 ml) was added and N₂ was flushed through the mixture for 5 minutes. Diisopropyl (*E*)-diazene-1,2-dicarboxylate (0.39 g, 1.92 mmol) was added dropwise and the solution was stirred at room temperature. After three hours another equivalent of reagents was added and stirred
5 for one hour. After removing the solvent by evaporation the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed
10 by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 0.319 g methyl 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate (yield 39%).

¹HNMR (300 MHz, CDCl₃): δ 3.15 (t, 2H), 3.95 (s, 3H), 4.2 (t, 2H), 5.07 (s, 2H), 5.6 (s,
15 2H), 6.9 – 7.1 (bm, 7H), 7.3 – 7.55 (bm, 7H), 7.6 (t, 1H), 7.85 (d, 1H), 8.05 (d, 1H)

c) Methyl 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate (0.275 g, 0.59 mmol) was dissolved in dichloromethane (10 ml), dimethylsulfide (0.44 g, 7.0 mmol) and borontrifluoride etherate (0.83 g, 5.87 mmol) was added and the mixture was stirred at
20 room temperature for six hours. EtOAc (10 ml) was added and the organic phase was washed with water (3 X 10 ml), dried (MgSO₄) and the solvent was removed by evaporation and the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column
25 KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions was pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). After removing the solvent by evaporation 0.096 gram of methyl 2-[(3-[2-(4-hydroxyphenoxy)ethyl]-phenoxy)methyl]benzoate was obtained (yield 43.2%). This product was used directly in
30 the next step.

d) Methyl 2-({3-[2-(4-hydroxyphenoxy)ethyl]phenoxy}methyl)benzoate (0.096 g, 0.25 mmol) was dissolved in dichloromethane (10 ml) and cooled to -20° C. Triethylamine (0.039g, 0.38 mmol) was added drop wise and methanesulfonyl chloride (0.032 g, 0.28 mmol) was added drop wise. The ice bath was removed and the mixture was warmed to room temperature. Diethyl ether (5 ml) was added and the precipitate filtered off. The organic phase was washed with two portions of brine (5 ml) and dried (MgSO₄). Removing the solvent was removed by evaporation giving 0.109 gram of methyl 2-({3-[2-({4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenoxy]methyl}benzoate (yield 94.1%).

¹HNMR (500 MHz, CDCl₃): δ 3.15 (m, 5H), 3.95 (s, 3H), 4.2 (t, 2H), 5.55 (s, 2H), 6.95 (s, 4H), 7.0 (s, 1H), 7.25 (d, 2H), 7.3 (t, 1H), 7.42 (t, 1H), 7.6 (t, 1H), 7.8 (d, 1H), 8.1 (d, 1H).

e) Methyl 2-({3-[2-({4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenoxy]methyl}benzoate (0.109 g, 0.24 mmol) was dissolved in a mixture of THF/water (7/1, 2.5 ml). Lithium hydroxide (23 mg, 0.96 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). The mixture was acidified (HCl, 1 ml, 1 M) and the water phase was extracted with two portions of EtOAc (2 X 5 ml). The organic phases were combined, dried (MgSO₄) and the solvent was removed by evaporation and gave 17 mg of 2-({3-[2-({4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenoxy]methyl}benzoic acid (yield 16%).

¹HNMR (500 MHz, CDCl₃): δ 3.15 (m, 5H), 4.2 (t, 2H), 5.55 (s, 2H), 6.95 (s, 4H), 7.0 (s, 1H), 7.25 (d, 2H), 7.3 (t, 1H), 7.42 (t, 1H), 7.6 (t, 1H), 7.8 (d, 1H), 8.1 (d, 1H).

Example 17

a) 3-(2-Hydroxyethyl)phenol (1.0 g, 7.24 mmol) and methyl 2-(bromomethyl)benzoate (1.74 g, 7.6 mmol) was dissolved in acetonitrile (10 ml). Potassium carbonate anhydrous (2.0 g, 14.48 mmol) was added. After stirring at 60°C for three hours PS-trisamine was added (0.3 eq) and was stirred overnight. The PS-trisamine was filtered off and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer was washed with 3 portions of water (3 X 10 ml). The organic phase was dried (MgSO₄)

and the solvent was removed by evaporation to give 1.99 g of methyl 2-[[3-(2-hydroxyethyl)phenoxy]methyl]benzoate (yield 90%).

¹HNMR (300 MHz, CDCl₃): δ 2.95 (t, 2H), 3.45 (s, 1H), 3.9 – 4.0 (bm, 5H), 5.58 (s, 2H),
5 6.95 (m, 2H), 7.05 (s, 1H), 7.3 (t, 1H), 7.45 (t, 1H), 7.6 (t, 1H), 7.85 (d, 1H), 8.05 (d, 1H)

b) Methyl 2-[[3-(2-hydroxyethyl)phenoxy]methyl]benzoate (0.5g, 1.75 mmol), 4-(benzyloxy)phenol (0.35 g, 1.75 mmol) and triphenylphosphine (0.5 g, 1.92 mmol) was added to a dry round bottomed flask and fitted with septum. Dry toluene (10 ml) was
10 added and N₂ was flushed through the mixture for 5 minutes. Diisopropyl (*E*)-diazene-1,2-dicarboxylate (0.39 g, 1.92 mmol) was added dropwise and the solution was stirred at room temperature. After three hours another equivalent of reagents was added and stirred for one hour. After removing the solvent by evaporation the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile
15 concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 0.319 g
20 methyl 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate (yield 39%).

¹HNMR (300 MHz, CDCl₃): δ 3.15 (t, 2H), 3.95 (s, 3H), 4.2 (t, 2H), 5.07 (s, 2H), 5.6 (s, 2H), 6.9 – 7.1 (bm, 7H), 7.3 – 7.55 (bm, 7H), 7.6 (t, 1H), 7.85 (d, 1H), 8.05 (d, 1H)

25 c) Methyl 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenoxy)methyl]benzoate (0.275 g, 0.59 mmol) was dissolved in dichloromethane (10 ml), dimethyl sulfide (0.44 g, 7.0 mmol) and borontrifluoride etherate (0.83 g, 5.87 mmol) was added and the mixture was stirred at room temperature for six hours. EtOAc (10 ml) was added and the organic phase was washed with water (3 X 10 ml), dried (MgSO₄) and the solvent was removed by
30 evaporation and the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column

KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). After removing the solvent by evaporation 0.096 gram of methyl 2-({3-[2-(4-hydroxyphenoxy)ethyl]-phenoxy}methyl)benzoate was obtained (yield 43.2%). This product was used directly in the next step.

d) Methyl 2-({3-[2-(4-hydroxyphenoxy)ethyl]phenoxy}methyl)benzoate (0.096 g, 0.25 mmol) was dissolved in dichloromethane (10 ml) and cooled to -20° C. Triethylamine (0.039g, 0.38 mmol) was added drop wise and methanesulfonyl chloride (0.032 g, 0.28 mmol) was added drop wise. The ice bath was removed and the mixture was warmed to room temperature. Add diethyleter (5 ml) and filter of the precipitate, wash the organic phase with two portions of brine (5 ml) and dry (MgSO₄). Removing the solvent by evaporation gave 0.109 gram of methyl 2-{{3-[2-(4-[(methanesulfonyl)oxy]phenoxy)ethyl]-phenoxy}methyl}benzoate (yield 94.1%).

¹HNMR (500 MHz, CDCl₃): δ 3.15 (m, 5H), 3.95 (s, 3H), 4.2 (t, 2H), 5.55 (s, 2H), 6.95 (s, 4H), 7.0 (s, 1H), 7.25 (d, 2H), 7.3 (t, 1H), 7.42 (t, 1H), 7.6 (t, 1H), 7.8 (d, 1H), 8.1 (d, 1H).

f) Methyl 2-{{3-[2-(4-[(methanesulfonyl)oxy]phenoxy)ethyl]phenoxy}methyl}benzoate (0.109 g, 0.24 mmol) was dissolved in a mixture of THF/water (7/1, 2.5 ml). Lithium hydroxide (23 mg, 0.96 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). The mixture was acidified (HCl, 1 ml, 1 M) and the water phase was extracted with two portions of EtOAc. The organic phases were combined, dried (MgSO₄) and the solvent was removed by evaporation and gave 16 mg of 2-({3-[2-(4-hydroxyphenoxy)ethyl]phenoxy}methyl)benzoic acid (yield 18%)

¹HNMR (400 MHz, CDCl₃): δ 3.0 (t, 2H), 4.1 (t, 2H), 5.55 (s, 2H), 6.7 (m, 4H), 6.8-6.95 (bm, 3H), 7.4 (m, 1H), 7.6 (m, 1H), 7.8 (m, 1H), 8.15 (m, 1H).

Example 18

a) 4-(3-Hydroxypropyl)phenol (1.0 g, 6.57 mmol) and methyl 2-(bromomethyl)benzoate (1.66 g, 7.23 mmol) was dissolved in acetonitrile (10 ml). Potassium carbonate (1.82 g, 13.14 mmol) was added and the mixture was stirred at 60° C for three hours. Polymersupported trisamine (0.3 eqv) was added and the solution was stirred at room temperature over night. The PS-trisamine was filtered of and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer was washed with 3 portions of water (3 X 10 ml). The organic phase was dried (MgSO₄) and the solvent was removed by evaporation to give 1.66 gram of methyl 2-([4-(3-hydroxypropyl)phenoxy]-methyl)benzoate (yield 84.2%).

¹HNMR (500 MHz, CDCl₃): δ 1.9 (m, 2H), 2.65 (t, 2H), 3.25 (s, 1H), 3.65 (t, 2H), 3.85 (s, 3H), 5.45 (s, 2H), 6.95 (d, 2H), 7.15 (d, 2H), 7.35 (t, 1H), 7.5 (t, 1H), 7.75 (d, 1H), 8.05 (d, 1H).

b) Methyl 2-([4-(3-hydroxypropyl)phenoxy]methyl)benzoate (0.50 g, 1.66 mmol) and 4-(benzyloxy)phenol (0.33 g, 1.66 mmol) was added to a dry round bottomed flask fitted with a septum. Dry toluene (10 ml) was added and N₂ was flushed through the mixture for 5 minutes. (Tributylphosphoranylidene)acetonitrile (0.80 g, 3.33 mmol) was added dropwise and the reaction was performed in a single mode microwave oven. After removing the solvent by evaporation the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 0.515 gram of methyl 2-([4-(3-(4-(benzyloxy)phenoxy)propyl)phenoxy]methyl)benzoate (yield 64.1%).

¹HNMR (500 MHz, CDCl₃): δ 2.15 (m, 2H), 2.85 (t, 2H), 4.0 (m, 5H), 5.1 (s, 2H), 5.6 (s, 2H), 6.9-7.1 (bm, 6H), 7.22 (d, 2H), 7.35-7.55 (bm, 6H), 7.62 (t, 1H), 7.9 (d, 1H), 8.15 (d, 1H).

5 c) Methyl 2-[(4-{3-[4-(benzyloxy)phenoxy]propyl}phenoxy)methyl]benzoate (0.047 g, 0.097 mmol) was dissolved in a mixture of THF/water (7/1, 2 ml) and lithium hydroxide (9.3 mg, 0.39 mmol) was added. The reaction was performed in a single node microwave oven (7 min, 150° C). The reaction mixture was acidified (HCl, 1 M, 1 ml) and the water phase was washed with two portions of EtOAc (2 X 5 ml). The organic phases were
10 combined, dried (MgSO₄) and the solvent was removed by evaporation. The crude product was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the
15 acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 2 mg of 2-[(4-{3-[4-(benzyloxy)phenoxy]propyl}phenoxy)methyl]-benzoic acid (yield 4.4%).

20 ¹HNMR (500 MHz, CDCl₃): δ 2.05 (m, 2H), 2.75 (t, 2H), 4.0 (t, 2H), 5.05 (s, 2H), 5.6 (s, 2H), 6.8-7.0 (bm, 6H), 7.15 (d, 2H), 7.35-7.55 (bm, 6H), 7.55 (t, 1H), 7.8 (d, 1H), 8.15 (d, 1H).

Example 19

25

a) 4-(3-Hydroxypropyl)phenol (1.0 g, 6.57 mmol) and methyl 2-(bromomethyl)benzoate (1.66 g, 7.23 mmol) was dissolved in acetonitrile (10 ml). Potassium carbonate (1.82 g, 13.14 mmol) was added and the mixture was stirred at 60° C for three hours. Polymersupported trisamine (0.3 eqv) was added and the solution was stirred at room
30 temperature overnight. The PS-trisamine was filtered off and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer was washed with 3 portions of water (3 X 10 ml). The organic phase was dried (MgSO₄) and the solvent was

removed by evaporation to give 1.66 gram of methyl 2-[[4-(3-hydroxypropyl)phenoxy]-methyl]benzoate (yield 84.2%).

¹HNMR (500 MHz, CDCl₃): δ 1.9 (m, 2H), 2.65 (t, 2H), 3.25 (s, 1H), 3.65 (t, 2H), 3.85 (s, 3H), 5.45 (s, 2H), 6.95 (d, 2H), 7.15 (d, 2H), 7.35 (t, 1H), 7.5 (t, 1H), 7.75 (d, 1H), 8.05 (d, 1H).

b) Methyl 2-[[4-(3-hydroxypropyl)phenoxy]methyl]benzoate (0.50 g, 1.66 mmol) and 4-(benzyloxy)phenol (0.33 g, 1.66 mmol) was added to a dry round bottomed flask and fitted with septa. Dry toluene (10 ml) was added and N₂ was flushed through the mixture for 5 minutes. (Tributylphosphoranylidene)acetonitrile (0.80 g, 3.33 mmol) was added dropwise and the reaction was performed in a single node microwave oven.. After removing the solvent by evaporation the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 0.515 gram of methyl 2-[(4-{3-[4-(benzyloxy)phenoxy]-propyl}phenoxy)methyl]benzoate (yield 64.1%).

¹HNMR (500 MHz, CDCl₃): δ 2.15 (m, 2H), 2.85 (t, 2H), 4.0 (m, 5H), 5.1 (s, 2H), 5.6 (s, 2H), 6.9-7.1 (bm, 6H), 7.22 (d, 2H), 7.35-7.55 (bm, 6H), 7.62 (t, 1H), 7.9 (d, 1H), 8.15 (d, 1H).

c) Methyl 2-[(4-{3-[4-(benzyloxy)phenoxy]propyl}phenoxy)methyl]benzoate (0.70 g, 1.45 mmol) was dissolved in dichloromethane (10 ml). Dimethylsulfide (1.08 g, 17.4 mmol) and boron trifluoride etherate (2.06 g, 14.5 mmol) was added and the mixture was stirred at room temperature for six hours. EtOAc (10 ml) was added and the organic phase was washed with water (3 X 10 ml), dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a

mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). After removing the solvent by evaporation 0.328 gram of methyl 2-({4-[3-(4-hydroxyphenoxy)propyl]-phenoxy}methyl)benzoate (yield 57.6%) was obtained.

¹HNMR (500 MHz, CDCl₃): δ 2.05 (m, 2H), 2.75 (t, 2H), 3.9 (m, 5H), 5.5 (s, 2H), 6.65-6.8 (bm, 4H), 6.95 (d, 2H), 7.15 (d, 2H), 7.4 (t, 1H), 7.55 (t, 1H), 7.8 (d, 1H), 8.05 (d, 1H).

d) Methyl 2-({4-[3-(4-hydroxyphenoxy)propyl]phenoxy}methyl)benzoate (0.32 g, 0.81 mmol) was dissolved in dichloromethane (10 ml) and cooled to -20° C. Triethylamine (0.123g, 1.22 mmol) was added drop wise and methanesulfonyl chloride (0.10 g, 0.89 mmol) was added drop wise. The ice bath was removed and the mixture was warmed to room temperature. Diethyl ether (5 ml) was added and the precipitate was filtered off. The organic phase was washed with two portions of brine (5 ml) and dried (MgSO₄). Removing the solvent by evaporation gave 0.37 gram of methyl 2-{{4-[3-{4-[(methanesulfonyl)oxy]-phenoxy}propyl]phenoxy}methyl}benzoate (yield 97.3%).

¹HNMR (500 MHz, CDCl₃): δ 2.1 (m, 2H), 2.75 (t, 2H), 3.15 (s, 3H), 3.9 (m, 5H), 5.5 (s, 2H), 6.9-7.0 (bm, 4H), 7.15 (d, 2H), 7.22 (d, 2H), 7.4 (t, 1H), 7.55 (t, 1H), 7.8 (d, 1H), 8.05 (d, 1H).

e) Methyl 2-{{4-[3-{4-[(methanesulfonyl)oxy]phenoxy}propyl]phenoxy}methyl}benzoate (0.38 g, 0.81 mmol) was dissolved in a mixture of THF/water (7/1, 4 ml) and lithium hydroxide (9.3 mg, 0.39 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). The reaction mixture was acidified (HCl, 1 M, 1 ml) and the water phase was washed with two portions of EtOAc (2 X 5 ml). The organic phases were combined, dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X

250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 88 mg of 2-{{4-(3-{4-[(methylsulfonyl)oxy]phenoxy}propyl)phenoxy}-methyl}benzoic acid (yield 23.7%).

¹HNMR (500 MHz, CDCl₃): δ 2.1 (m, 2H), 2.75 (t, 2H), 3.15 (s, 3H), 3.95 (t, 2H), 5.58 (s, 2H), 6.9-7.05 (bm, 4H), 7.15-7.25 (bm, 4H), 7.45 (t, 1H), 7.65 (t, 1H), 7.85 (d, 1H), 8.2 (d, 1H).

Example 20

a) 4-(3-Hydroxypropyl)phenol (1.0 g, 6.57 mmol) and methyl 2-(bromomethyl)benzoate (1.66 g, 7.23 mmol) was dissolved in acetonitrile (10 ml). Potassium carbonate (1.82 g, 13.14 mmol) was added and the mixture was stirred at 60° C for three hours. Polymer supported trisamine (0.3 eqv) was added and the solution was stirred at room temperature overnight. The PS-trisamine was filtered off and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic layer was washed with 3 portions of water (3 X 10 ml). The organic phase was dried (MgSO₄) and the solvent was removed by evaporation to give 1.66 gram of methyl 2-{{4-(3-hydroxypropyl)phenoxy}-methyl}benzoate (yield 84.2%).

¹HNMR (500 MHz, CDCl₃): δ 1.9 (m, 2H), 2.65 (t, 2H), 3.25 (s, 1H), 3.65 (t, 2H), 3.85 (s, 3H), 5.45 (s, 2H), 6.95 (d, 2H), 7.15 (d, 2H), 7.35 (t, 1H), 7.5 (t, 1H), 7.75 (d, 1H), 8.05 (d, 1H).

b) Methyl 2-{{4-(3-hydroxypropyl)phenoxy}methyl}benzoate (0.50 g, 1.66 mmol) and 4-(benzyloxy)phenol (0.33 g, 1.66 mmol) was added to a dry round bottomed flask and fitted with a septum. Dry toluene (10 ml) was added and N₂ was flushed through the mixture for 5 minutes. (Tributylphosphoranylidene)acetonitrile (0.80 g, 3.33 mmol) was added drop wise and the reaction was performed in a single node microwave oven. After removing the solvent by evaporation the crude was purified by preparative HPLC (started with

acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 0.515 gram of methyl 2-[(4-{3-[4-(benzyloxy)phenoxy]propyl}phenoxy)methyl]benzoate (yield 64.1%).

¹HNMR (500 MHz, CDCl₃): δ 2.15 (m, 2H), 2.85 (t, 2H), 4.0 (m, 5H), 5.1 (s, 2H), 5.6 (s, 2H), 6.9-7.1 (bm, 6H), 7.22 (d, 2H), 7.35-7.55 (bm, 6H), 7.62 (t, 1H), 7.9 (d, 1H), 8.15 (d, 1H).

c) Methyl 2-[(4-{3-[4-(benzyloxy)phenoxy]propyl}phenoxy)methyl]benzoate (0.70 g, 1.45 mmol) was dissolved in dichloromethane (10 ml). Dimethylsulfide (1.08 g, 17.4 mmol) and borontrifluoride etherate (2.06 g, 14.5 mmol) was added and the mixture was stirred at room temperature for six hours. EtOAc (10 ml) was added and the organic phase was washed with water (3 X 10 ml), dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). After removing the solvent by evaporation 0.328 gram of methyl 2-[(4-{3-[4-(4-hydroxyphenoxy)propyl]phenoxy)methyl]benzoate (yield 57.6%) was obtained.

¹HNMR (500 MHz, CDCl₃): δ 2.05 (m, 2H), 2.75 (t, 2H), 3.9 (m, 5H), 5.5 (s, 2H), 6.65-6.8 (bm, 4H), 6.95 (d, 2H), 7.15 (d, 2H), 7.4 (t, 1H), 7.55 (t, 1H), 7.8 (d, 1H), 8.05 (d, 1H).

d) Methyl 2-[(4-{3-[4-(4-hydroxyphenoxy)propyl]phenoxy)methyl]benzoate (0.32 g, 0.81 mmol) was dissolved in dichloromethane (10 ml) and cooled to -20° C. Triethylamine (0.123g, 1.22 mmol) was added drop wise and methanesulfonyl chloride (0.10 g, 0.89

61

mmol) was added drop wise. The ice bath was removed and the mixture was warmed to room temperature. Diethyl ether (5 ml) was added and the precipitate was filtered off. The organic phase was washed with two portions of brine (5 ml) and dried (MgSO₄). Removing the solvent by evaporation gave 0.37 gram of methyl 2-[[4-(3-{4-
5 [(methylsulfonyl)oxy]phenoxy}propyl)phenoxy]methyl]benzoate (yield 97.3%).

¹HNMR (500 MHz, CDCl₃): δ 2.1 (m, 2H), 2.75 (t, 2H), 3.15 (s, 3H), 3.9 (m, 5H), 5.5 (s, 2H), 6.9-7.0 (bm, 4H), 7.15 (d, 2H), 7.22 (d, 2H), 7.4 (t, 1H), 7.55 (t, 1H), 7.8 (d, 1H), 8.05 (d, 1H).

10 e) Methyl 2-[[4-(3-{4-[(methylsulfonyl)oxy]phenoxy}propyl)phenoxy]methyl]benzoate (0.38 g, 0.81 mmol) was dissolved in a mixture of THF/water (7/1, 4 ml) and lithium hydroxide (9.3 mg, 0.39 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). The reaction mixture was acidified (HCl, 1 M, 1 ml) and
15 the water phase was washed with two portions of EtOAc (2 X 5 ml). The organic phases were combined, dried (MgSO₄) and the solvent was removed by evaporation the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X
20 250 mm, flow 40 ml/min). The product containing fractions was pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 63 mg of 2-([4-[3-(4-hydroxyphenoxy)propyl]phenoxy]methyl)benzoic acid (yield 20.5%).

25 ¹HNMR (500 MHz, CDCl₃): δ 2.05 (m, 2H), 2.75 (t, 2H), 3.9 (t, 2H), 5.58 (s, 2H), 6.65-6.8 (bm, 4H), 6.95 (d, 2H), 7.15 (d, 2H), 7.4 (t, 1H), 7.65 (t, 1H), 7.85 (d, 1H), 8.2 (d, 1H).

Example 21

30 a) 2-(2-Ethoxyphenyl)ethanamine (0.55 g, 3.33 mmol) and 3-(4-hydroxyphenyl)propanoic acid (0.50 g, 3.00 mmol) was dissolved in dimethyl formamide (5 ml) and cooled to 0° C.

N-[(1*H*-1,2,3-benzotriazol-1-yloxy)(dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (1.18 g, 3.66 mmol) and diisopropylethylamine (0.90 g, 7.0 mmol) were added and the solution was warmed to room temperature and stirred overnight. EtOAc (15 ml) was added and the organic phase was washed with two portions of sodium hydrogencarbonate (aq, 10 ml). The organic phase was dried (MgSO₄) and EtOAc was removed by evaporation to give 0.98 gram of *N*-[2-(2-ethoxyphenyl)ethyl]-3-(4-hydroxyphenyl)propanamide (yield 93.9%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 1.42 (t, 3H), 2.42 (t, 2H), 2.8-2.92 (m, 4H), 3.55 (q, 2H), 4.05 (q, 2H), 6.08 (m, 1H), 6.82-6.93 (m, 4H), 6.96-7.1 (m, 3H), 7.22 (t, 1H).

b) *N*-[2-(2-ethoxyphenyl)ethyl]-3-(4-hydroxyphenyl)propanamide (0.35 g, 1.12 mmol) and methyl 2-(bromomethyl)benzoate (0.28 g, 1.23 mmol) was dissolved in acetonitrile (5 ml) and potassium carbonate (324 mg, 2.34 mmol) was added. The mixture was stirred at 60° C for three hours. Polymersupported trisamine (0.3 eqv) was added and stirred overnight. The polymer was filtered off, solvent was removed by evaporation, addition of EtOAc (10 ml) and the organic phase was washed with three portions of water. After drying the crude (MgSO₄) and the solvent was removed by evaporation, the crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 26 mg of methyl 2-[[4-(3-[[2-(2-ethoxyphenyl)ethyl]amino]-3-oxopropyl)phenoxy]methyl]benzoate (yield 50.4%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 1.38 (t, 3H), 2.35 (t, 2H), 2.76 (t, 2H), 2.85 (t, 2H), 3.45 (q, 2H), 3.86 (s, 3H), 3.99 (q, 2H), 5.44 (s, 2H), 5.84 (m, 1H), 6.78-6.9 (m, 4H), 6.96-7.03 (m, 3H), 7.15 (t, 1H), 7.32 (t, 1H), 7.5 (t, 1H), 7.72 (d, 1H), 8.0 (d, 1H).

c) Methyl 2-{{[4-(3-{{[2-(2-ethoxyphenyl)ethyl]amino}-3-oxopropyl]phenoxy)methyl]-benzoate (0.26 g, 0.56 mmol) was dissolved in a mixture of THF/water (7/1, 5 ml) and lithium hydroxide (54 mg, 2.25 mmol) was added. The reaction was performed in a single node microwave oven (7 min, 150° C). The reaction mixture was acidified (HCl, 1 M, 1 ml) and the water phase was washed with two portions of EtOAc (2 X 5 ml). The organic phases were combined, dried (MgSO₄) and the solvent was removed by evaporation. The crude product was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 136 mg of 2-{{[4-(3-{{[2-(2-ethoxyphenyl)ethyl]amino}-3-oxopropyl]phenoxy)methyl]benzoic acid (yield 53.9%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 1.42 (t, 3H), 2.38 (t, 2H), 2.8 (t, 2H), 2.9 (t, 2H), 3.42 (q, 2H), 3.99 (q, 2H), 5.55 (s, 2H), 6.81-6.95 (m, 4H), 7.05-7.17 (m, 4H), 7.38 (t, 1H), 7.55 (m, 1H), 7.81 (d, 1H), 8.11 (d, 1H)

Example 22

a) *N*-Ethyl-*N*-(2-pyridin-2-ylethyl)amine (0.5 g, 3.32 mmol) and 3-(4-hydroxyphenyl)propanoic acid (0.50 g, 3.00 mmol) was dissolved in dimethylformamide (5 ml) and cooled to 0° C. *N*-[(1*H*-1,2,3-benzotriazol-1-yloxy)(dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (1.18 g, 3.66 mmol) and diisopropylethylamine (0.90 g, 7.0 mmol) were added and the solution was warmed to room temperature and stirred overnight. EtOAc (15 ml) was added and the organic phase was washed with two portions of sodium hydrogencarbonate (aq, 10 ml). The organic phase was dried (MgSO₄) and EtOAc was removed by evaporation to give 0.913 gram of *N*-ethyl-3-(4-hydroxyphenyl)-*N*-(2-pyridin-2-ylethyl)propanamide (yield 91.9%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 0.97, 1.05 (t, t, 3H), 2.41, 2.52 (t, t, 2H), 2.75-3.0 (m, 4H), 3.09, 3.33 (q, q, 2H), 3.54, 3.61 (t, t, 2H), 6.74-6.82 (m, 2H), 6.93-7.2 (m, 4H), 7.58 (m, 1H), 8.48 (m, 1H).

- 5 b) *N*-Ethyl-3-(4-hydroxyphenyl)-*N*-(2-pyridin-2-ylethyl)propanamide (0.35 g, 1.17 mmol) and methyl 2-(bromomethyl)benzoate (0.30 g, 1.29 mmol) were dissolved in acetonitrile (5 ml) and potassium carbonate (324 mg, 2.34 mmol) was added. The mixture was stirred at 60° C for three hours. Polymer supported trisamine (0.3 eqv) was added and stirred overnight. The polymer was filtered off, solvent was removed by evaporation, EtOAc (10
10 ml) was added and the organic phase was washed with three portions of water. After drying the organic layer (MgSO₄), the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X
15 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 135 mg of methyl 2-[(4-{3-[ethyl(2-pyridin-2-ylethyl)amino]-3-oxopropyl}phenoxy)methyl]benzoate (yield 25.8%).

20 ¹HNMR (Rotamers, 600 MHz, CDCl₃): δ 0.97, 1.05 (t, t, 3H), 2.41, 2.52 (t, t, 2H), 2.75-3.0 (m, 4H), 3.09, 3.33 (q, q, 2H), 3.54, 3.61 (t, t, 2H), 3.83 (s, 3H), 5.43 (s, 2H), 6.75-6.85 (m, 2H), 6.93-7.2 (m, 4H), 7.3 (t, 1H), 5.42 (m, 2H), 7.7 (d, 1H), 7.97 (d, 1H), 8.48 (m, 1H).

- 25 c) Methyl 2-[(4-{3-[ethyl(2-pyridin-2-ylethyl)amino]-3-oxopropyl}phenoxy)methyl]benzoate (0.135 g, 0.30 mmol) was dissolved in a mixture of THF/water (7/1, 5 ml) and lithium hydroxide (29 mg, 1.2 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). The reaction mixture was acidified (HCl, 1 M, 1
30 ml) and the water phase was washed with two portions of EtOAc (2 X 5 ml). The organic phases were combined, dried (MgSO₄) and the solvent was removed by evaporation. The crude product was purified by preparative HPLC (started with acetonitrile/buffer 60/40 and

then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min)). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase
5 was washed with two portions of brine and dried (MgSO₄). Removing the solvent by evaporation gave 27 mg of 2-[(4-{3-[ethyl(2-pyridin-2-ylethyl)amino]-3-oxopropyl}phenoxy)methyl]benzoic acid (yield 20.6%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 1.02, 1.12 (t, t, 3H), 2.48, 2.59 (t, t, 2H), 2.85-
10 3.43 (m, 6H), 3.58, 3.66 (t, t, 2H), 5.51, 5.53 (s, s, 2H), 6.86-6.96 (m, 2H), 7.06-7.33 (m, 4H), 7.4 (t, 1H), 5.56 (t, 1H), 7.64-7.75 (m, 2H), 8.14 (m, 1H), 8.64 (m, 1H)

Example 23

a) 1-(2-Bromoethyl)-3-*tert*-butoxybenzene

15 3-(2-Bromoethyl)phenol (1.349 g, 6.709 mmol) in DCM (7 ml) was cooled under argon to -78 °C. Under stirring, isobutene was bubbled into the mixture until more than 5 ml were added. Trifluoromethanesulphonic acid (50 µl) was dropped in. The mixture was stirred under argon at -78 °C for 4.5 hours. Triethylamine (120 µl) was added. The reaction
20 mixture was allowed up to room temperature and then filtered. The filtrate was evaporated to dryness and petroleum ether (25 ml) was added into the residue. It was then filtered and evaporated. The obtained oil was solved in ethyl acetate, washed with water, dried (sodium sulphate) and evaporated. The residue was dissolved in CDCl₃ and then evaporated. 1.223 g desired product was left, yield 71%.

25 ¹H NMR (500 MHz, CDCl₃): δ 1.42 (s, 9H), 3.17 (t, 2H), 3.59 (t, 2H), 6.92-6.98 (m, 3H) and 7.25 (t, 1H).

b) Methyl 2-[(2-(3-*tert*-butoxyphenyl)ethyl)thio]benzoate

30 1-(2-Bromoethyl)-3-*tert*-butoxybenzene (320 mg, 1.244 mmol) was dissolved in acetonitrile (15 ml). Methyl thiosalicylate (209 mg, 1.244 mmol) was added and then potassium carbonate, anhydrous (258 mg, 1.866 mmol) was added. The mixture was

heated to reflux for 3 hours and then evaporated under vacuum to dryness.

Chromatography of the residue on a column (ISOLUTE® SI, 5g/25 ml) using ethyl acetate/heptane (5:95) as eluant gave 421 mg desired product, yield 98%.

¹H NMR (500 MHz, CDCl₃): δ 1.39 (s, 9H), 3.00 (t, 2H), 3.21 (t, 2H), 3.96 (s, 3H), 6.90-6.93 (m, 2H), 7.01 (d, 1H), 7.19-7.26 (m, 2H), 7.38 (d, 1H), 7.48 (t, 1H) and 8.00 (d, 1H).

c) Methyl 2-([2-(3-hydroxyphenyl)ethyl]thio)benzoate

Methyl 2-([2-(3-*tert*-butoxyphenyl)ethyl]thio)benzoate (402 mg, 1.167 mmol) was dissolved in DCM (3 ml). Trifluoroacetic acid (3 ml) was added. The mixture was stirred overnight and then evaporated to dryness. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6ml) using ethyl acetate/heptane (2.5:97.5, then 5:95, then 10:90 and then 25:75) as eluant gave 260 mg the desired product, yield 77%.

¹H NMR (500 MHz, CDCl₃): δ 2.94 (t, 2H), 3.17 (t, 2H), 3.95 (s, 3H), 6.18 (s, 1H) 6.77-6.83 (m, 3H), 7.18 (t, 2H), 7.34 (d, 1H), 7.44 (t, 1H) and 7.99 (d, 1H).

d) N-benzyl-2-bromo-N-hexylacetamide

N-hexylbenzylamine (4.2 g, 21.953 mmol) and triethylamine (3.98 ml, 28.539 mmol) were mixed in DCM (20 ml) and cooled in an ice-bath. Bromoacetyl chloride (3.455 mg, 21.953 mmol) in DCM (5 ml) was added. The mixture was stirred over weekend and the temperature was allowed going up to room temperature. The mixture was washed with water mixed with 1% hydrochloric acid (water phase pH~4-5) and brine, dried with magnesium sulphate, and evaporated. Column chromatography of the residue on silica gel using ethyl acetate/heptane (10:90, then 20:80) as eluant gave 4.0 g desired product, yield 58%.

¹H NMR (rotamers, 300 MHz, CDCl₃): δ 0.85-0.92 (m, 3H), 1.28 (s, br, 6H), 1.53-1.62 (m, 2H), 3.25, 3.39 (t, t, 2H), 4.05, 4.16 (s, s, 2H), 4.61, 4.63 (s, s, 2H) and 7.19-7.42 (m, 5H).

e) Methyl 2-([2-(3-{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)ethyl]thio)benzoate

Methyl 2-([2-(3-hydroxyphenyl)ethyl]thio)benzoate (129 mg, 0.447 mmol), *N*-benzyl-2-bromo-*N*-hexylacetamide (154 mg, 0.492 mmol) and potassium carbonate, anhydrous (93 mg, 0.671 mmol) were mixed in acetonitrile (10 ml). The mixture was heated to reflux overnight and then evaporated to dryness. Water and ethyl acetate were added into the residue. The two phases were separated. The organic phase was washed with brine and dried with magnesium sulphate and then evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6ml) using ethyl acetate/heptane (10:90, then 25:75) as eluant gave 208 mg the desired product, yield 89.5%.

¹H NMR (rotamers, 500 MHz, CDCl₃): δ 0.86-0.91 (m, 3H), 1.24-1.32 (m, 6H), 1.53-1.64 (m, 2H), 2.94-3.03 (m, 2H), 3.13-3.20 (m, 2H), 3.29, 3.41 (t, t, 2H), 3.93 (s, 3H), 4.64, 4.65 (s, s, 2H), 4.71, 4.81 (s, s, 2H), 6.75-6.77 (m, 1H), 6.85-6.93 (m, 2H), 7.17-7.39 (m, 8H), 7.46 (t, 1H) and 7.99 (d, 1H).

¹³C NMR (rotamers, 125 MHz, CDCl₃): δ 13.85, 13.86, 22.39, 26.38, 27.03, 28.27, 31.31, 31.37, 33.28, 34.51, 34.57, 46.34, 48.13, 50.33, 51.94, 67.13, 67.38, 112.33, 112.39, 114.84, 114.96, 121.48, 121.56, 123.79, 125.49, 126.40, 127.24, 127.54, 127.64, 127.89, 128.42, 128.74, 129.48, 129.57, 131.17, 132.22, 136.51, 137.03, 141.30, 141.74, 141.87, 158.06, 158.15, 166.75, 167.74 and 167.88.

f) 2-([2-(3-{2-[Benzyl(hexyl)amino]-2-oxoethoxy}phenyl)ethyl]thio)benzoic acid

Methyl 2-([2-(3-{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)ethyl]thio)benzoate (80 mg, 0.154 mmol) in tetrahydrofuran (3 ml) was cooled in an ice-bath. Lithium hydroxide (7.4 mg, 0.308 mmol) in water (3 ml) was added. The cooling bath was then removed and the mixture was stirred for 12 days and then evaporated in vacuum to remove tetrahydrofuran. The residue was acidified with 1% hydrochloric acid, pH=3, and extracted with ethyl acetate. The organic phase was dried with magnesium sulphate and evaporated. Chromatography of the residue on a column (ISOLUTE® SI, 2g/6 ml) using DCM, MeOH/DCM (1:99, and then 2:98) as eluant gave 27 mg product mixture. Re-chromatography of the mixture on a column (ISOLUTE® SI, 1g/6ml) using DCM and then MeOH/AcOH/DCM (0.25:0.25:99.5) as eluant gave 17 mg desired product, yield 22%.

¹H NMR (rotamers, 500 MHz, CDCl₃): δ 0.85-0.90 (m, 3H), 1.23-1.31 (m, 6H), 1.53-1.63 (m, 2H), 2.91-3.00 (m, 2H), 3.11-3.20 (m, 2H), 3.29, 3.41 (t, t, 2H), 4.65, 4.66 (s, s, 2H), 4.74, 4.83 (s, s, 2H), 6.72-6.93 (m, 3H), 7.20-7.32 (m, 6H), 7.37 (t, 2H), 7.47 (t, 1H) and 8.09 (d, 1H).

¹³C NMR (rotamers, 125 MHz, CDCl₃): δ 13.98, 22.51, 26.51, 27.11, 28.36, 31.42, 31.49, 34.16, 34.60, 34.66, 46.52, 48.35, 50.52, 67.20, 67.47, 112.60, 115.15, 115.29, 121.66, 121.75, 124.46, 126.54, 126.80, 127.42, 127.70, 128.04, 128.56, 128.89, 129.59, 129.67, 132.13, 132.79, 136.46, 136.98, 141.16, 141.75, 141.89, 158.08, 158.17, 168.25, 168.37 and 169.60.

Example 24

AR-H072686

a) Heptan-1-amine (1 g, 8.679 mmol) was dissolved in DMF (10 ml), (2-methoxyphenyl)acetic acid (1.587 g, 9.547 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-benzotriazol-1-yloxy)(dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (3.065, 9.547 mmol) and *N*-ethyl-*N,N*-diisopropylamine (2.356g, 18.226 mmol) were added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the organic phase was washed with two portions of NaHCO₃ (2 X 20 ml, aq). The organic layer was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 2.00 g of *N*-heptyl-2-(2-methoxyphenyl)acetamide (yield 87.5%).

¹H NMR (500 MHz, CDCl₃): δ 0.75 (t, 3H), 1.10 (m, 8H), 1.28 (m, 2H), 3.02 (q, 2H), 3.39 (s, 2H), 3.45 (s, 3H), 6.2 (bs, 1H), 6.75 (m, 2H), 7.08 (m, 2H).

b) *N*-Heptyl-2-(2-methoxyphenyl)acetamide (2.00 g, 7.594 mmol) was dissolved in THF (10 ml) and was cooled to zero degrees under argon atmosphere. (Methylthio)methane compound with borane (1:1) (1.442 g, 18.984 mmol) was added and the mixture was refluxed for 5 hours. After the mixture was cooled to room temperature, 5 ml HCl (10%) was gently added and the mixture was stirred overnight. The solvent was removed by evaporation. EtOAc (20 ml) was added and the organic phase was washed with K₂CO₃ (2M, 2 X 20 ml). The crude was purified by flash chromatography (started with isocratic heptane/EtOAc 50/50 and then the EtOAc concentration was increased to 100%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation to give 1.037 g of *N*-[2-(2-methoxyphenyl)ethyl]heptan-1-amine (yield 54.8%).

¹HNMR (300 MHz, CDCl₃): δ 0.83 (t, 3H), 1.07 (s, 1H), 1.13 (m, 8H), 1.43 (m, 2H), 2.57 (m, 2H), 2.80 (s, 4H), 3.72 (s, 3H), 6.8 (bm, 2H), 7.08 (m, 2H).

c) *N*-[2-(2-Methoxyphenyl)ethyl]heptan-1-amine (0.091 g, 0.366 mmol) was dissolved in DMF (5 ml), (4-[[2-(methoxycarbonyl)benzyl]oxy]phenyl)acetic acid (0.100 g, 0.333 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-Benzotriazol-1-yl)oxy](dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (0.118g, 0.366 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.090 g, 0.699 mmol) were added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the organic phase was washed with two portions of water (2 X 20 ml). The organic layer was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.094 g of methyl 2-[[4-(2-{[heptyl[2-(2-methoxyphenyl)ethyl]amino}-2-oxoethyl)phenoxy]methyl]benzoate (yield 53.1%).

¹HNMR (Rotamers, 400 MHz, CDCl₃): δ 0.85 (t, 3H), 1.13 (m, 8H), 1.43 (m, 2H), 2.7-3.75 (m, 8H), 3.77-3.95 (bm, 6H), 5.5 (m, 2H), 6.8-7.45 (bm, 9H), 7.55 (q, 1H), 7.73 (q, 1H), 8.03 (3H).

- 5 d) Methyl 2-[[4-(2-{heptyl[2-(2-methoxyphenyl)ethyl]amino}-2-oxoethyl)phenoxy]methyl]benzoate (0.094 g, 0.177 mmol) was dissolved in EtOH (5 ml, 95%), potassium hydroxide (0.015 g, 0.265 mmol) was added. The reaction was performed in an single node microwave oven (7 min, 150 deg). Workup by removing the solvent by evaporation and addition of HCl (2 ml, 1 M). The waterphase was extracted with two
- 10 portions of EtOAc (20 ml) and the organic phase was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing
- 15 fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). The solvent was removed by evaporation to give 0.011 g of 2-[[4-(2-{heptyl[2-(2-methoxyphenyl)ethyl]amino}-2-oxoethyl)phenoxy]methyl]benzoic acid (yield 12%).
- ¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 0.85 (t, 3H), 1.13 (m, 8H), 1.43 (m, 2H), 2.7-3.75 (m, 8H), 3.77-3.95 (bm, 3H), 5.5 (m, 2H), 6.8-7.45 (bm, 9H), 7.55 (q, 1H), 7.73 (q, 1H), 8.03 (3H).
- 20

Example 25

25 AR-H072687

- a) Heptan-1-amine (1 g, 8.679 mmol) was dissolved in dry THF under N₂ and polymer supported *N*-benzyl-*N,N*-diisopropylamine (4.955 g, 26.038 mmol) was added. The mixture was stirred for 30 min and cooled to 0 degrees and (4-chlorophenyl)acetyl chloride (1.969 g, 10.415 mmol) was added. The solution was stirred overnight at room
- 30 temperature. The excess of (4-chlorophenyl)acetyl chloride was removed by filtering the mixture through an NH₂ cartridge. The solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then

the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase
5 was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 1.045 g of 2-(4-chlorophenyl)-*N*-heptylacetamide (yield 45.0%).

¹HNMR (500 MHz, CDCl₃): δ 0.82 (t, 3H), 1.2 (m, 8H), 1.39 (m, 2H), 3.12 (t, 2H), 3.43 (s, 2H), 6.35 (bs, 1H), 7.15 (d, 2H), 7.23 (d, 2H).

10 b) 2-(4-Chlorophenyl)-*N*-heptylacetamide (0.886 g, 3.797 mmol) was dissolved in THF (10 ml) and was cooled to zero degrees under argon atmosphere. (Methylthio)methane compound with borane (1:1) (0.741 g, 9.755 mmol) was added and the mixture was refluxed for 5 hours. After the mixture was cooled to room temperature, 5 ml HCl (10%) was gently added and the mixture was stirred overnight. The solvent was removed by
15 evaporation. EtOAc (20 ml) was added and the organic phase was washed with K₂CO₃ (2M, 2 X 20 ml). The crude was purified by flash chromatography (started with isocratic heptane/EtOAc 50/50 and then the EtOAc concentration was increased to 100%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation to give 0.609 g of *N*-[2-(4-chlorophenyl)ethyl]-*N*-heptylamine
20 (yield 61.5%).

¹HNMR (300 MHz, CDCl₃): δ 0.85 (t, 3H), 1.22 (m, 8H), 1.39 (m, 2H), 2.52 (t, 2H), 2.45-2.6 (t, 2H), 2.6-2.82 (m, 4H), 7.0-7.2 (bm, 2H).

c) *N*-[2-(4-Chlorophenyl)ethyl]-*N*-heptylamine (0.093 g, 0.366 mmol) was dissolved in
25 DMF (5 ml). (4-[[2-(Methoxycarbonyl)benzyl]oxy]phenyl)acetic acid (0.100 g, 0.333 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-Benzotriazol-1-yl)oxy](dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (0.118g, 0.366 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.090 g, 0.699 mmol) were added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the
30 organic phase was washed with two portions of water (2 X 20 ml). The organic layer was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile

concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.112 g of methyl 2-[(4-{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}phenoxy)methyl]benzoate (yield 62.7%).

¹HNMR (Rotamers, 300 MHz, CDCl₃): δ 0.85 (t, 3H), 1.22 (m, 8H), 1.39 (m, 2H), 2.62-3.7 (bm, 8H), 3.9 (m, 3H), 5.45-5.55 (m, 2H), 6.89-7.43 (bm, 9H), 7.52 (m, 1H), 7.75 (t, 1H), 8.02 (t, 1H).

d) Methyl 2-[(4-{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}phenoxy)methyl]benzoate (0.112 g, 0.209 mmol) was dissolved in EtOH (5 ml, 95%) and potassium hydroxide (0.018 g, 0.313 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150 deg). Workup was by removing the solvent by evaporation and addition of HCl (2 ml, 1 M). The water-phase was extracted with two portions of EtOAc (20 ml) and the organic phase was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). The solvent was removed by evaporation to give 0.006 g of 2-[(4-{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}phenoxy)methyl]benzoic acid (yield 5.5%).

¹HNMR (Rotamers, 300 MHz, CDCl₃): δ 0.85 (t, 3H), 1.22 (m, 8H), 1.39 (m, 2H), 2.62-3.7 (bm, 8H), 5.45-5.55 (m, 2H), 6.89-7.43 (bm, 9H), 7.52 (m, 1H), 7.78 (t, 1H), 8.13 (t, 1H).

Example 26

AR-H072688

a) Heptan-1-amine (1 g, 8.679 mmol) was dissolved in dry THF under N₂ and polymer supported *N*-benzyl-*N,N*-diisopropylamine (4.955 g, 26.038 mmol) was added. The mixture was stirred for 30 min and cooled to 0 degrees and phenylacetyl chloride (1.610 g, 10.415 mmol) was added. The solution was stirred overnight at room temperature. The excess of phenylacetyl chloride was removed by filtering the mixture through an NH₂ cartridge. The solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.886 g of *N*-heptyl-2-phenylacetamide (yield 43.7 %).

¹HNMR (500 MHz, CDCl₃): δ 0.82 (t, 3H), 1.22 (m, 8H), 1.39 (m, 2H), 3.12 (t, 2H), 3.45 (s, 2H), 6.45 (bs, 1H), 7.18-7.3 (bm, 5H).

b) *N*-Heptyl-2-phenylacetamide (0.886 g, 3.797 mmol) was dissolved in THF (10 ml) and was cooled to zero degrees under argon atmosphere. (Methylthio)methane compound with borane (1:1) (0.721 g, 9.492 mmol) was added and the mixture was refluxed for 5 hours. After the mixture was cooled to room temperature, 5 ml HCl (10%) was gently added and was stirred overnight. The solvent was removed by evaporation. EtOAc (20 ml) was added and the organic phase was washed with K₂CO₃ (2M, 2 X 20 ml). The crude was purified by flash chromatography (started with isocratic heptane/EtOAc 50/50 and then the EtOAc concentration was increased to 100%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation to give 0.584 g of *N*-(2-phenylethyl)heptan-1-amine (yield 70.1%).

¹HNMR (300 MHz, CDCl₃): δ 0.85 (t, 3H), 1.25 (m, 8H), 1.43 (m, 2H), 2.6 (t, 2H), 2.7-2.95 (bm, 4H), 7.1-7.35 (bm, 5H).

c) *N*-(2-Phenylethyl)heptan-1-amine (0.080 g, 0.366 mmol) was dissolved in DMF (5 ml), (4-[[2-(methoxycarbonyl)benzyl]oxy]phenyl)acetic acid (0.100 g, 0.333 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-Benzotriazol-1-yl)oxy](dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (0.118 g, 0.366 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.090 g, 0.699 mmol) were added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the organic phase was washed with two portions of water (2 X 20 ml). The organic layer was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.146 g of methyl 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}phenoxy)methyl]-benzoate (yield 87.4%).

¹HNMR (Rotamers, 400 MHz, CDCl₃): δ 0.85 (t, 3H), 1.1-1.35 (bm, 8H), 1.4-1.6 (bm, 2H), 2.65-65 (m, 8H), 3.9 (m, 3H), 5.43-5.56 (m, 2H), 6.85-7.4 (bm, 10H), 7.52 (m, 1H), 7.73 (t, 1H), 8.02 (t, 1H).

20

d) Methyl 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}phenoxy)methyl]benzoate (0.146 g, 0.291 mmol) was dissolved in EtOH (5 ml, 95%), potassium hydroxide (0.025 g, 0.437 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). Work-up was by removing the solvent by evaporation and addition of HCl (2 ml, 1 M). The water-phase was extracted with two portions of EtOAc (20 ml) and the organic phase was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). The solvent was removed by

30

evaporation to give 0.043 g of 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}-phenoxy)methyl]benzoic acid (yield 30.3%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 0.85 (t, 3H), 1.1-1.35 (bm, 8H), 1.4-1.6 (bm, 2H), 2.65-6.5 (m, 8H), 5.43-5.56 (m, 2H), 6.9-7.45 (bm, 10H), 7.57 (m, 1H), 7.78 (t, 1H), 8.17 (t, 1H).

Example 27

AR-H075101

- 10 a) *N*-(2-Fluorobenzyl)ethanamine (0.248 g, 0.993) was dissolved in DMF (10 ml), (4-hydroxyphenoxy)acetic acid (0.150 g, 0.903 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-benzotriazol-1-yl)oxy](dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (0.319 g, 0.993 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.245 g, 1.896 mmol) were added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the organic phase was washed with two portions of Na₂CO₃ (2 X 20 ml, aq). The organic layer was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, 20 column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.177 g of *N*-ethyl-*N*-(2-fluorobenzyl)-2-(4-hydroxyphenoxy)acetamide (yield 64.6%).
- 25 ¹HNMR (Rotamers, 300 MHz, CDCl₃): δ 1.02-1.25 (m, 3H), 3.4 (q, 2H), 4.68 (m, 4H), 6.65-6.85 (bm, 4H), 6.95-7.4 (m, 4H).

- 30 b) *N*-Ethyl-*N*-(2-fluorobenzyl)-2-(4-hydroxyphenoxy)acetamide (0.177 g, 0.586 mmol) was dissolved in acetonitrile (10 ml), methyl 2-(bromomethyl)benzoate (0.147 g, 0.642 mmol) and dipotassium carbonate (0.161 g, 1.167 mmol) were added. The solution was stirred for 2 hours at 60° C. EtOAc (20 ml) was added and the organic phase was washed with two portions of brine (2 X 20 ml, aq). The organic layer was dried (MgSO₄) and the

solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product
5 containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.242 g of methyl 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenoxy)methyl]benzoate (yield 91.9%).

¹HNMR (Rotamers, 300 MHz, CDCl₃): δ 1.02-1.28 (m, 3H), 3.39 (m, 2H), 3.89 (s, 3H)
10 4.6-4.75 (m, 4H), 5.42 (d, 2H), 6.75-7.42 (bm, 9H), 7.55 (t, 1H), 7.72 (t, 1H), 8.0 (d, 1H).

c) Methyl 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenoxy)methyl]-benzoate (0.242 g, 0.536 mmol) was dissolved in EtOH (5 ml, 95%), potassium hydroxide (0.060 g, 1.072 mmol) was added. The reaction was performed in an single node
15 microwave oven (7 min, 150° C). Work-up was by removing the solvent by evaporation and addition of HCl (2 ml, 1 M). The water-phase was extracted with two portions of EtOAc (20 ml) and the organic phase was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by flash chromatography (started with isocratic DCM 100% and then the MeOH concentration was increased from 0.5% to 20%, (silica gel 60
20 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation to give 0.160 g of 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenoxy)methyl]benzoic acid (yield 68.2%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 1.07-1.28 (m, 3H), 3.42 (m, 2H), 4.62-4.78 (m, 4H), 5.48 (d, 2H), 6.78-7.37 (bm, 8H), 7.40 (m, 1H), 7.60 (q, 1H), 7.80 (t, 1H), 8.18 (d,
25 1H).

Example 28

AR-H075104

30 a) *N*-(2-Fluorobenzyl)ethanamine (0.077 g, 0.500 mmol) was dissolved in DMF (10 ml), (4-[[2-(methoxycarbonyl)phenoxy]methyl]phenyl)acetic acid (0.150 g, 0.500 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-benzotriazol-1-

5 yloxy)(dimethylamino)methylene]-*N*-methylethanaminium tetrafluoroborate (0.176 g, 0.549 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.136 g, 1.049 mmol) was added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the organic phase was washed with two portions of Na₂CO₃ (2 X 20 ml, aq). The organic layer was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.146 g of methyl 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethyl}benzyl)oxy]benzoate (yield 67.1%).

15 ¹HNMR (Rotamers, 400 MHz, CDCl₃): δ 1.02-1.15 (m, 3H), 3.25-3.5 (m, 2H), 3.65-3.8 (m, 2H), 3.88 (s, 3H), 4.5-4.7 (bm, 2H), 5.17 (m, 2H), 6.92-7.5 (bm, 11H), 7.8 (m, 2H).

b) Methyl 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethyl}benzyl)oxy]benzoate (0.242 g, 0.555 mmol) was dissolved in EtOH (5 ml, 95%), potassium hydroxide (0.062 g, 1.111 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). Work-up by removing the solvent by evaporation and addition of HCl (2 ml, 1 M). The water-phase was extracted with two portions of EtOAc (20 ml) and the organic phase was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by flash chromatography (started with isocratic DCM 100% and then the MeOH concentration was increased from 0.5% to 20%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation to give 0.013 g of 2-[(4-{2-[ethyl(2-fluorobenzyl)amino]-2-oxoethyl}benzyl)oxy]benzoic acid (yield 5.6%).

25 ¹HNMR (Rotamers, 400 MHz, CDCl₃): δ 1.1 (t, 3H), 3.3-3.5 (bm, 2H), 3.7-3.82 (m, 2H), 4.55-4.7 (bm, 2H), 5.23 (d, 2H), 6.95-7.45 (bm, 11H), 7.55 (t, 3H), 8.22 (d, 1H).

Example 29

AR-H075106

a) Heptan-1-amine (1 g, 8.679 mmol) was dissolved in dry THF under N₂ and polymer supported *N*-benzyl-*N,N*-diisopropylamine (4.955 g, 26.038 mmol) was added. The mixture was stirred for 30 min and cooled to 0° C and phenylacetyl chloride (1.610 g, 10.415 mmol) was added. The solution was stirred overnight at room temperature. The excess of phenylacetyl chloride was removed by filtering the mixture through an NH₂ cartridge. The solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.886 g of *N*-heptyl-2-phenylacetamide (yield 43.7 %).

¹HNMR (500 MHz, CDCl₃): δ 0.82 (t, 3H), 1.22 (m, 8H), 1.39 (m, 2H), 3.12 (t, 2H), 3.45 (s, 2H), 6.45 (bs, 1H), 7.18-7.3 (bm, 5H).

b) *N*-Heptyl-2-phenylacetamide (0.886 g, 3.797 mmol) was dissolved in THF (10 ml) and was cooled to 0° C under argon atmosphere. (Methylthio)methane compound with borane (1:1) (0.721 g, 9.492 mmol) was added and the mixture was refluxed for 5 hours. After the mixture was cooled to room temperature, 5 ml HCl (10%) was gently added and the mixture was stirred overnight. The solvent was removed by evaporation. EtOAc (20 ml) was added and the organic phase was washed with K₂CO₃ (2M, 2 X 20 ml). The crude was purified by flash chromatography (started with isocratic heptane/EtOAc 50/50 and then the EtOAc concentration was increased to 100%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation to give 0.584 g of *N*-(2-phenylethyl)heptan-1-amine (yield 70.1%).

¹HNMR (300 MHz, CDCl₃): δ 0.85 (t, 3H), 1.25 (m, 8H), 1.43 (m, 2H), 2.6 (t, 2H), 2.7-2.95 (bm, 4H), 7.1-7.35 (bm, 5H).

c) *N*-(2-Phenylethyl)heptan-1-amine (0.110 g, 0.500 mmol) was dissolved in DMF (10 ml), (4-{{2-(methoxycarbonyl)phenoxy}methyl}phenyl)acetic acid (0.150 g, 0.500 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-benzotriazol-1-yl)oxy](dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (0.176g, 0.549 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.136 g, 1.049 mmol) were added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the organic phase was washed with two portions of Na₂CO₃ (2 X 20 ml, aq). The organic layer was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 0.229 g of methyl 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}benzyl)oxy]benzoate (yield 91.4%).

¹HNMR (Rotamers, 400 MHz, CDCl₃): δ 0.85 (m, 3H), 1.25 (m, 8H), 1.40-1.6 (m, 2H), 2.75-3.7 (bm, 8H), 3.9 (m, 3H), 5.17 (d, 2H), 6.96-7.5 (bm, 12H), 7.8 (t, 1H).

d) Methyl 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}benzyl)oxy]benzoate (0.229 g, 0.457 mmol) was dissolved in EtOH (5 ml, 95%) and potassium hydroxide (0.051 g, 0.913 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). Work-up was by removing the solvent by evaporation and addition of HCl (2 ml, 1 M). The water-phase was extracted with two portions of EtOAc (20 ml) and the organic phase was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by flash chromatography (started with isocratic DCM 100% and then the MeOH concentration was increased from 0.5% to 20%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation. The product was not pure and was therefore purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40

ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). The solvent was removed by evaporation to give 0.025 g of 2-[(4-{2-[heptyl(2-phenylethyl)amino]-2-oxoethyl}benzyl)oxy]benzoic acid (yield 11.2%).

¹HNMR (Rotamers, 400 MHz, CDCl₃): δ 0.85 (m, 3H), 1.25 (m, 8H), 1.40-1.62 (m, 2H), 2.75-3.7 (bm, 8H), 5.23 (d, 2H), 7.05-7.6 (bm, 12H), 8.2 (t, 1H).

Example 30

AR-H075107

a) Heptan-1-amine (1 g, 8.679 mmol) was dissolved in dry THF under N₂ and polymer supported *N*-benzyl-*N,N*-diisopropylamine (4.955 g, 26.038 mmol) was added. The mixture was stirred for 30 min and cooled to 0° C and (4-chlorophenyl)acetyl chloride (1.969 g, 10.415 mmol) was added. The solution was stirred overnight at room temperature. The excess of (4-chlorophenyl)acetyl chloride was removed by filtering the mixture through an NH₂ cartridge. The solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄) and the solvent was removed by evaporation to give 1.045 g of 2-(4-chlorophenyl)-*N*-heptylacetamide (yield 45.0%).

¹HNMR (500 MHz, CDCl₃): δ 0.82 (t, 3H), 1.22 (m, 8H), 1.35 (m, 2H), 3.12 (q, 2H), 3.40 (s, 2H), 6.35 (bs, 1H), 7.1-7.3 (bm, 4H).

b) 2-(4-Chlorophenyl)-*N*-heptylacetamide (1.045 g, 3.902 mmol) was dissolved in THF (10 ml) and was cooled to 0° C under argon atmosphere. (Methylthio)methane compound with borane (1:1) (0.741 g, 9.756 mmol) was added and the mixture was refluxed for 5 hours. After the mixture was cooled to room temperature, 5 ml HCl (10%) was gently added and was stirred overnight. The solvent was removed by evaporation. EtOAc (20 ml)

was added and the organic phase was washed with K_2CO_3 (2M, 2 X 20 ml). The crude was purified by flashchromatography (started with isocratic heptane/EtOAc 50/50 and then the EtOAc concentration was increased to 100%, (silica gel 60 0.004-0.063 mm). The product containing fractions was pooled and the EtOAc was removed by evaporation to give 0.609 g of *N*-[2-(4-chlorophenyl)ethyl]-*N*-heptylamine (yield 61.5%).

1H NMR (300 MHz, $CDCl_3$): δ 0.82 (t, 3H), 1.22 (m, 8H), 1.38 (m, 2H), 2.52 (t, 2H), 2.6-2.85 (bm, 4H), 7.0-7.3 (bm, 4H).

c) *N*-[2-(4-Chlorophenyl)ethyl]-*N*-heptylamine (0.127 g, 0.500 mmol) was dissolved in DMF (10 ml), (4-{[2-(methoxycarbonyl)phenoxy]methyl}phenyl)acetic acid (0.150 g, 0.500 mmol) was added and the mixture was cooled to 0° C. *N*-[(1*H*-1,2,3-benzotriazol-1-yl)oxy](dimethylamino)methylene]-*N*-methylmethanaminium tetrafluoroborate (0.176g, 0.549 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.136 g, 1.049 mmol) was added. The solution was stirred overnight at room temperature. EtOAc (20 ml) was added and the organic phase was washed with two portions of Na_2CO_3 (2 X 20 ml, aq). The organic layer was dried ($MgSO_4$) and the solvent was removed by evaporation. The crude was purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions were pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried ($MgSO_4$) and the solvent was removed by evaporation to give 0.224 g of methyl 2-[(4-{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}benzyl)oxy]benzoate (yield 83.7%).

1H NMR (Rotamers, 400 MHz, $CDCl_3$): δ 0.85 (m, 3H), 1.25 (m, 8H), 1.40-1.6 (m, 2H), 2.7-3.75 (bm, 8H), 3.9 (m, 3H), 5.17 (d, 2H), 6.96-7.5 (bm, 11H), 7.8 (t, 1H).

d) Methyl 2-[(4-{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}benzyl)oxy]benzoate (0.224 g, 0.418 mmol) was dissolved in EtOH (5 ml, 95%) and potassium hydroxide (0.047 g, 0.836 mmol) was added. The reaction was performed in a single mode microwave oven (7 min, 150° C). Work-up was by removing the solvent by evaporation and addition of HCl (2 ml, 1 M). The water-phase was extracted with two portions of

EtOAc (20 ml) and the organic phase was dried (MgSO₄) and the solvent was removed by evaporation. The crude was purified by flash chromatography (started with isocratic DCM 100% and then the MeOH concentration was increased from 0.5% to 20%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation. The product was not pure and was therefore purified by preparative HPLC (started with isocratic acetonitrile/buffer 60/40 and then the acetonitrile concentration was increased to 100%, the buffer was a mixture of acetonitrile/water 10/90 and ammonium acetate (0.1 M, column KR-100-7-C8, 50 mm X 250 mm, flow 40 ml/min). The product containing fractions was pooled and the acetonitrile was removed by evaporation. EtOAc (10 ml) was added and the organic phase was washed with two portions of brine and dried (MgSO₄). The solvent was removed by evaporation to give 0.154 g of 2-[(4-{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}benzyl)oxy]-benzoic acid (yield 76.8%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 0.85 (m, 3H), 1.25 (m, 11H), 1.40-1.62 (m, 2H), 2.7-3.7 (bm, 10H), 4.5 (d, 2H), 7-7.4 (bm, 8H).

Example 31

AR-H075135

a) *N*-Isobutyl-*N*-[4-(trifluoromethyl)benzyl]amine (0.172 g, 0.746 mmol) was dissolved in dry acetonitrile under N₂ and *N*-ethyl-*N,N*-diisopropylamine (0.371 g, 2.867 mmol) was added. The mixture was stirred for 30 min and methyl 2-{2-[4-(2-chloro-2-oxoethoxy)phenyl]ethoxy}benzoate (0.200 g, 0.573 mmol) was added. The solution was stirred over night at room temperature. The crude was purified by flash chromatography (started with isocratic heptane/EtOAc 50/50 and then the EtOAc concentration was increased to 100%, (silica gel 60 0.004-0.063 mm). The product containing fractions were pooled and the EtOAc was removed by evaporation to give 0.242 g of methyl 2-{2-[4-(2-{isobutyl[4-(trifluoromethyl)benzyl]amino}-2-oxoethoxy)phenyl]ethoxy}benzoate (yield 77.6%).

¹HNMR (Rotamers, 500 MHz, CDCl₃): δ 0.82-0.97 (bm, 6H), 2.0 (m, 1H), 3.02-3.24 (m, 4H), 3.88 (s, 3H), 4.18 (m, 2H), 4.62-4.8 (m, 4H), 6.78-7.0 (m, 4H), 7.1-7.32 (m, 4H) 7.35-7.62 (m, 3H), 7.78 (d, 1H).

b) Methyl 2-{2-[4-(2-{isobutyl[4-(trifluoromethyl)benzyl]amino}-2-oxoethoxy)phenyl]-ethoxy}benzoate (0.242 g, 0.455 mmol) was dissolved in a mixture of THF (freshly distilled)/ water (2/1, 3 ml), lithium hydroxide (0.218 g, 0.909 mmol) was added. The reaction was performed in a single node microwave oven (5 min, 150 deg). THF was removed by evaporation. Water was added (10ml) and the basic water phase was washed with diethyl ether (2 X 10 ml). Addition of HCl (2 ml, 1 M, pH 1). The water phase was extracted with two portions of DCM (20 ml), the organic phase was dried (MgSO₄) and the solvent was removed by evaporation to give 0.135 g of 2-{2-[4-(2-{isobutyl[4-(trifluoromethyl)benzyl]amino}-2-oxoethoxy)phenyl]ethoxy}benzoic acid (yield 57.3%).
¹HNMR (Rotamers, 400 MHz, CDCl₃): δ 0.82-0.97 (bm, 6H), 1.98 (m, 1H), 3.06-3.24 (m, 4H), 4.4 (m, 2H), 4.62-4.8 (m, 4H), 6.8 (d, 1H), 6.92 (d, 1H), 7.01 (m, 1H), 7.03-7.22 (m, 3H), 7.27 (m, 2H), 7.5 (m, 2H), 7.58 (d, 1H), 8.1 (d, 1H).

Biological activity

Formulations

Compounds were dissolved in DMSO to obtain 16 mM stock solutions. Before assays, stock solutions were further diluted in DMSO and culture media.

GENERAL CHEMICALS AND REAGENTS

Luciferase assay reagent was purchased from Packard, USA. Restriction Enzymes were from Boehringer and Vent polymerase from New England Biolabs.

CELL LINES AND CELL CULTURE CONDITIONS

U2-OS, (Osteogenic sarcoma, Human) was purchased from ATCC, USA. Cells were expanded and refrozen in batches from passage number six. Cells were cultured in Dulbecco's modified Eagle medium (DMEM) with 25 mM glucose, 2 mM glutamine or 4 mM L-alanyl-L-glutamine, 10% fetal calf serum, at 5% CO₂. Phosphate buffered saline (PBS) without addition of calcium or magnesium was used. All cell culture reagents were from Gibco (USA) and 96-well cell culture plates were purchased from Wallach.

PLASMID CONSTRUCTS FOR HETEROLOGOUS EXPRESSION

Standard recombinant DNA techniques were carried out as described by Ausubel (7). The Luciferase reporter vector, pGL5UAS (clone consists of five copies of the GAL4 DNA binding sequence, 5'-CGACGGAGTACTGTCCTCCGAGCT-3', cloned into the SacI/XhoI sites of pGL3-Promoter (Promega). The SacI/XhoI fragment carrying the UAS sites was constructed using annealed overlapping oligonucleotides.

Expression vectors used are based upon pSG5 (Stratagene). All vectors contain an EcoRI/NheI fragment encoding the DNA binding domain of GAL4 (encoding amino acid positions 1-145 of database accession number P04386) followed by an in-frame fusion to a fragment encoding the nuclear localisation sequence from T antigen of Polyoma Virus. The nuclear localisation sequence was constructed using annealed overlapping oligonucleotides creating NheI/KpnI sticky ends (5'-CTAGCGCTCCTAGAAGAAACGCAAGGTTGGTAC-3'). The ligand binding domains from human and mouse PPAR α and human and mouse PPAR γ were PCR amplified as KpnI/BamHI fragments and cloned in frame to the GAL4 DNA binding domain and the nuclear localisation sequence. The sequence of all plasmid constructs used were confirmed by sequencing.

The following expression vectors were used for transient transfections:

vector	encoded PPAR subtype	sequence reference ¹
pSGGALhPPa	human PPAR α	S74349, nt 625-1530
pSGGALmPPa	murine PPAR α	X57638, nt 668-1573
pSGGALhPPg	human PPAR γ	U63415, nt 613-1518
pSGGALmPPg	murine PPAR γ	U09138, nt 652-1577

1 refers to nucleotide positions of data base entry used to express the ligand binding domain.

TRANSIENT TRANSFECTIONS

5 Frozen stocks of cells from passage number six were thawed and expanded to passage number eight before transfections. Confluent cells were trypsinised, washed and pelleted by centrifugation at 270xg for 2 minutes. The cell pellet was resuspended in cold PBS to a cell concentration of about 18×10^6 cells/ml. After addition of DNA, the cell suspension was incubated on ice for approximately 5 minutes before electroporation at 230 V, 960 μ F
10 in Biorad's Gene PulserTM in 0.5 ml batches. A total of 50 μ g DNA was added to each batch of 0.5 ml cells, including 2.5 μ g expression vector, 25 μ g reporter vector and 22.5 μ g unspecific DNA (pBluescript, Stratagene).

After electroporation, cells were diluted to a concentration of 320'000 cells/ml in DMEM
15 without phenol red, and approximately 25'000 cells/well were seeded in 96-well plates. In order to allow cells to recover, seeded plates were incubated at 37°C for 3-4 hours before addition of test compounds. In assays for PPAR α , the cell medium was supplemented with resin-charcoal stripped fetal calf serum (FCS) in order to avoid background activation by fatty acid components of the FCS. The resin-charcoal stripped FCS was produced as
20 follows; for 500 ml of heat-inactivated FCS, 10 g charcoal and 25 g Bio-Rad Analytical Grade Anion Exchange Resin 200-400 mesh were added, and the solution was kept on a magnetic stirrer at room temperature over night. The following day, the FCS was centrifuged and the stripping procedure was repeated for 4-6 hours. After the second treatment, the FCS was centrifuged and filter sterilised in order to remove remnants of
25 charcoal and resin.

ASSAY PROCEDURE

Stock solutions of compounds in DMSO were diluted in appropriate concentration ranges in master plates. From master plates, compounds were diluted in culture media to obtain test compound solutions for final doses.

5

After adjustment of the amount of cell medium to 75 μ l in each well, 50 μ l test compound solution was added. Transiently transfected cells were exposed to compounds for about 24 hours before the luciferase detection assay was performed. For luciferase assays, 100 μ l of assay reagent was added manually to each well and plates were left for approximately 20 minutes in order to allow lysis of the cells. After lysis, luciferase activity was measured in a 1420 Multiwell counter, Victor, from Wallach.

10

Reference compounds

The TZD pioglitazone was used as reference substance for activation of both human and murine PPAR γ . 5,8,11,14-Eicosatetrayonic acid (ETYA) was used as reference substance for human PPAR α .

15

Calculations and analysis

For calculation of EC₅₀ values, a concentration-effect curve was established. Values used were derived from the average of two or three independent measurements (after subtraction of the background average value) and were expressed as the percentage of the maximal activation obtained by the reference compound. Values were plotted against the logarithm of the test compound concentration. EC₅₀ values were estimated by linear intercalation between the data points and calculating the concentration required to achieve 50% of the maximal activation obtained by the reference compound.

20


25

The compound of formula I have an EC₅₀ of less than 50 μ mol/l for PPAR α and/or PPAR γ . Preferred compounds have an EC₅₀ of less than 5 μ mol/l for either PPAR α or PPAR γ . For

example, Example 2 has an EC_{50} of $2.96 \mu\text{mol/l}$ for human PPAR alpha and an EC_{50} of $3.05 \mu\text{mol/l}$ for mouse PPAR gamma.

Claims

1. A compound of formula I



5

wherein

R^1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted by one or more of the following groups:

10 a C_{1-6} alkyl group;

a C_{1-6} acyl group;

aryl C_{1-6} alkyl, wherein the alkyl, aryl, or alkylaryl group is optionally substituted by one or more R^b ;

halogen,

15 -CN and NO_2 ,

- NR^cCOOR^a ;

- NR^cCOR^a ;

- NR^cR^a ;

- $NR^cSO_2R^d$;

20 - $NR^cCONR^kR^c$;

- $NR^cCSNR^aR^k$;

- OR^a ;

- OSO_2R^d ;

- SO_2R^d ;

25 - SOR^d ;

- SR^c ;

- $SO_2NR^aR^f$;

-SO₂OR^a;

-CONR^cR^a;

-OCONR^fR^a;

wherein R^a represents H, a C₁₋₆alkyl group, aryl or arylC₁₋₆alkyl group wherein the alkyl,

5 aryl or arylC₁₋₆alkyl group is optionally substituted one or more times by R^b, wherein R^b represents C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, cyano, -NR^cR^d, =O, halo, -OH, -SH, -OC₁₋₄alkyl, -Oaryl, -OC₁₋₄alkylaryl, -COR^c, -SR^d, -SOR^d, or -SO₂R^d, wherein R^c represents H, C₁₋₄alkyl, aryl, arylC₁₋₄alkyl and R^d represents C₁₋₄alkyl, aryl, arylC₁₋₄alkyl;

wherein R^f represents hydrogen, C₁₋₄alkyl, C₁₋₄acyl, aryl, arylC₁₋₄alkyl and R^a is as defined

10 above; and

R^k represents hydrogen, C₁₋₄alkyl, aryl, arylC₁₋₄alkyl;

the group -(CH₂)_m-T-(CH₂)_n-U-(CH₂)_p- is attached at either the 3 or 4 position in the

phenyl ring as indicated by the numbers in formula I and represents a group selected from

15 one or more of the following: O(CH₂)₂, O(CH₂)₃, NC(O)NR⁴(CH₂)₂, CH₂S(O₂)NR⁵(CH₂)₂, CH₂N(R⁶)C(O)CH₂, (CH₂)₂N(R⁶)C(O)(CH₂)₂, C(O)NR⁷CH₂, C(O)NR⁷(CH₂)₂, and CH₂N(R⁶)C(O)CH₂O;

V represents O, S, NR⁸, or a single bond;

20

q represents 1, 2 or 3 ;

W represents O, S, N(R⁹)C(O), NR¹⁰, or a single bond;

25 R² represents halo, a C₁₋₄alkyl group which is optionally substituted by one or more fluoro, a C₁₋₄alkoxy group which is optionally substituted by one or more fluoro, a C₁₋₄acyl group, aryl, an arylC₁₋₄alkyl group, CN or NO₂ ;

r represents 0, 1, 2 or 3 ;

30

R^3 represents halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a C_{1-4} alkoxy group which is optionally substituted by one or more fluoro, a C_{1-4} acyl group, aryl, an aryl C_{1-4} alkyl group, or CN ;

5 s represents 0, 1, 2 or 3 ; and

R^4 , R^5 , R^6 , R^7 , R^8 , R^9 and R^{10} independently represent H, a C_{1-10} alkyl group, aryl or an aryl C_{1-4} alkyl group or when m is 0 and T represents a group $N(R^6)C(O)$ or a group $(R^5)NS(O_2)$ then R^1 and R^6 or R^1 and R^5 together with the nitrogen atom to which they are
10 attached represent a heteroaryl group;

and pharmaceutically acceptable salts thereof ;

with the provisos that when

1) when R^1 is phenyl optionally substituted by one or two groups independently selected from halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a
15 C_{1-4} alkoxy group which is optionally substituted by one or more fluoro;

m is 1;

T is $N(R^6)C(O)$ wherein R^6 represents a C_{2-8} alkyl group which is optionally interrupted by oxygen;

n is 1;

20 U is absent or represents methylene;

p is 0;

r is 0;

V is O or S;

q is 1; and

25 W is a single bond attached to the position ortho to the carboxylic acid group;
then s does not represent 0; and

2) when R^1 is phenyl optionally substituted by one or two groups independently selected from halo, a C_{1-4} alkyl group which is optionally substituted by one or more fluoro, a
30 C_{1-4} alkoxy group which is optionally substituted by one or more fluoro;

m is 1;

T is $N(R^6)C(O)$ wherein R^6 represents an unbranched C_{2-7} alkyl group;

n is 1;

U is O;

p is 0;

r is 0 or 1;

5 and when r is 1 R² is attached at the 3 position and is OCH₃;

V is a single bond;

q is 2; and

W is O or S attached to the position ortho to the carboxylic acid group;

then s does not represent 0.

10

2. A compound according to claim 1 in which R¹ represents phenyl which is optionally substituted by one or more of the following: halo, hydroxy, a C₁₋₄alkyl group which is optionally substituted by one or more fluoro, a C₁₋₄alkoxy group which is optionally substituted by one or more fluoro, benzyloxy, a C₁₋₄alkylsulphonyloxy group, phenyl or a
 15 heteroaryl group, or R¹ represents heteroaryl which is optionally substituted by one or more of the following: halo, a C₁₋₄alkyl group which is optionally substituted by one or more fluoro, a C₁₋₄alkoxy group which is optionally substituted by one or more fluoro or phenyl optionally substituted by one or more of the following: halo, a C₁₋₄alkyl group which is optionally substituted by one or more fluoro, a C₁₋₄alkoxy group which is
 20 optionally substituted by one or more fluoro.

3. A compound according to any previous claim in which the group -(CH₂)_m-T-(CH₂)_n-U-(CH₂)_p- is attached at the 4 position in the phenyl ring as indicated by the numbers in formula I, that is para to the group V.

25

4. A compound according to any previous claim in which the group -V-(CH₂)_q-W- represents a group selected from : OCH₂, SCH₂, NHCH₂, CH₂CH₂S or CH₂CH₂O.


30

5. A compound according to any previous claim in which the group -V-(CH₂)_q-W- represents the group OCH₂.

6. A compound according to any previous claim in which the group $-V-(CH_2)_q-W-$ is joined at the ortho position with respect to the carboxylic acid group.
7. A compound according to any previous claim in which R^2 is halo, a C_{1-4} alkyl group or a C_{1-4} alkoxy group and r is 0 or 1.
8. A compound according to any previous claim in which s is 0.
9. A compound selected from one or more of the following:
 - 3-[[[(3-[(1,1'-biphenyl-4-ylcarbonyl)amino]methyl)phenyl]amino]methyl]benzoic acid;
 - 2-[[[4-(2-oxo-2-[[4-(trifluoromethyl)benzyl]amino]ethyl)phenoxy]methyl]benzoic acid;
 - 2-[(3-{2-[benzyl(hexyl)amino]-2-oxoethyl})phenoxy]methyl]benzoic acid;
 - 2-[[3-(2-oxo-2-[[4-(trifluoromethyl)benzyl]amino]ethyl)phenoxy]methyl]benzoic acid;
 - 2-[[4-{3-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-3-oxopropyl]phenoxy]-methyl]benzoic acid;
 - 2-[[4-{2-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]carbonyl]amino]ethyl]phenoxy]methyl]benzoic acid;
 - 2-[(4-{2-[[4-(2,4-difluorophenyl)amino]carbonyl]amino]ethyl)phenoxy]methyl]benzoic acid;
 - 2-[(4-{2-[(2-methyl-5-phenyl-3-furoyl)amino]ethyl})phenoxy]methyl]benzoic acid;
 - 2-[(4-{2-[(benzylsulfonyl)amino]ethyl})phenoxy]methyl]benzoic acid;
 - 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-fluorophenoxy]methyl]benzoic acid;
 - 2-[(4-{2-[benzyl(hexyl)amino]-2-oxoethyl}-2-methoxyphenoxy]methyl]benzoic acid;
 - 2-[(4-{3-(3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl]phenoxy]methyl]benzoic acid;
 - 2-[(4-{2-[4-(1H-imidazol-1-yl)]phenoxy]ethyl]-phenoxy]methyl]benzoic acid;
 - 2-[[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenoxy]methyl]benzoic acid;
 - 2-[(3-{2-[4-(benzyloxy)phenoxy]ethyl})phenoxy]methyl]benzoic acid;
 - 2-[[3-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenoxy]methyl]benzoic acid;
 - 2-[(3-{2-[4-(4-hydroxyphenoxy)ethyl]phenoxy}methyl]benzoic acid;
 - 2-[(4-{3-[4-(benzyloxy)phenoxy]propyl]phenoxy]methyl]benzoic acid;
 - 2-[[4-(3-{4-[(methylsulfonyl)oxy]phenoxy}propyl)phenoxy]methyl]benzoic acid;
 - 2-[(4-{3-[4-(4-hydroxyphenoxy)propyl]phenoxy}methyl]benzoic acid;

- 2-[[4-(3-{{2-(2-ethoxyphenyl)ethyl}amino}-3-oxopropyl)phenoxy)methyl]benzoic acid;
 2-[[4-(3-{{ethyl(2-pyridin-2-ylethyl)amino}-3-oxopropyl}phenoxy)methyl]benzoic acid;
 2-{{2-(3-{{2-[[benzyl(hexyl)amino]-2-oxoethoxy}phenyl]ethyl}thio}benzoic acid;
 2-[[4-(2-{{heptyl[2-(2-methoxyphenyl)ethyl]amino}-2-oxoethyl}phenoxy)methyl]benzoic
 5 acid;
 2-[[4-{{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}phenoxy)methyl]benzoic
 acid;
 2-[[4-{{2-[[heptyl(2-phenylethyl)amino]-2-oxoethyl]-phenoxy)methyl]benzoic acid;
 2-[[4-{{2-[[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenoxy)methyl]benzoic acid;
 10 2-[[4-{{2-[[ethyl(2-fluorobenzyl)amino]-2-oxoethyl}benzyl]oxy]benzoic acid;
 2-[[4-{{2-[[heptyl(2-phenylethyl)amino]-2-oxoethyl}benzyl]oxy]benzoic acid;
 2-{{2-[[4-(2-{{isobutyl[4-(trifluoromethyl)benzyl]amino}-2-oxoethoxy}phenyl]ethoxy}-
 benzoic acid; and
 2-[[4-{{2-[[2-(4-chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl}benzyl]oxy]benzoic acid
 15 and pharmaceutically acceptable salts thereof.

10. A pharmaceutical formulation comprising a compound according to any preceding
 claim in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
- 20 11. A method of treating or preventing insulin resistance comprising the administration
 of a compound according to any one of claims 1 to 9 to a mammal in need thereof.
12. The use of a compound according to any one of claims 1 to 9 in the manufacture of a
 medicament for the treatment of insulin resistance.
- 25 13. A process to prepare compounds of formula I comprising reacting a compound of
 formula II



II

in which R^1 , T , U , V , W , R^2 , R^3 , m , n , p , q , r and s are as previously defined and PG represents a protecting group for a carboxylic hydroxy group with a de-protecting agent.

- 5 14. Compounds of formula II as described in claim 13.

INTERNATIONAL SEARCH REPORT

International Application No.

PC/GB 03/02598

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/19 A61P3/06 A61P3/10 C07C65/24 C07C233/78
 C07C235/34 C07C309/66 C07C311/13 C07C323/62 C07D213/40
 C07D217/06 C07D277/56 C07D307/68 C07D233/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS, MEDLINE, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 113 871 A (BOEHRINGER MANNHEIM GMBH) 12 September 1978 (1978-09-12) abstract column 16; examples 14,14A column 19; examples 14,14A; table 1 ---	1-3,6,8, 10-14
A	WO 01 12187 A (ASTRAZENECA AB) 22 February 2001 (2001-02-22) abstract claims; examples; table 1 ---	1-14
A	WO 99 20275 A (RHONE-POULENC RORER PHARMACEUTICALS INC.) 29 April 1999 (1999-04-29) abstract; claims page 62; example 25; table IX page 25-26 --- -/-	1-14

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

16 October 2003

Date of mailing of the international search report

29/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Kiernan, A

INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/GB 03/02598

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 802 186 A (BAYER AG) 22 October 1997 (1997-10-22) abstract page 15; example 31; table 1 -----	1-14
A	US 6 306 854 B1 (GLAXOSMITHKLINE) 23 October 2001 (2001-10-23) abstract; claims column 3, line 25,26 -----	1-14
A	RAMI, H. K. ET AL.: "Synthetic ligands for PPAR gamma - review of patent literature 1994-1999" EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, no. 5, 2000, pages 623-623, XP002257971 cited in the application the whole document -----	1-14

INTERNATIONAL SEARCH REPORT

International application No.:
PCT/GB 03/02598

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 11 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/JP03/02598

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4113871	A	12-09-1978	DE 2517229 A1	28-10-1976
			DE 2604560 A1	11-08-1977
			AR 213174 A1	29-12-1978
			AT 349451 B	10-04-1979
			AT 101578 A	15-09-1978
			AT 345795 B	10-10-1978
			AT 283676 A	15-02-1978
			AT 349448 B	10-04-1979
			AT 475677 A	15-09-1978
			AU 497513 B2	14-12-1978
			AU 1315776 A	27-10-1977
			BE 840801 A1	15-10-1976
			BG 26518 A3	12-04-1979
			CA 1047513 A1	30-01-1979
			CS 188280 B2	28-02-1979
			DD 124974 A5	23-03-1977
			DK 148576 A	19-10-1976
			ES 446976 A1	01-06-1977
			FI 761004 A	19-10-1976
			FR 2307528 A1	12-11-1976
			GB 1484848 A	08-09-1977
			HU 177559 B	28-11-1981
			IE 42712 B1	08-10-1980
			IL 49411 A	30-12-1979
			JP 51136646 A	26-11-1976
			LU 74786 A1	12-01-1977
			NL 7603947 A	20-10-1976
			PL 101299 B1	30-12-1978
			PT 65019 A , B	01-05-1976
			RO 73520 A1	30-12-1980
			SE 423231 B	26-04-1982
			SE 7604381 A	19-10-1976
			SU 618038 A3	30-07-1978
			US 4238506 A	09-12-1980
			ZA 7602285 A	25-05-1977
WO 0112187	A	22-02-2001	AU 6583400 A	13-03-2001
			BR 0013368 A	07-05-2002
			CA 2380775 A1	22-02-2001
			CN 1379774 T	13-11-2002
			EP 1210343 A2	05-06-2002
			WO 0112187 A2	22-02-2001
			JP 2003507327 T	25-02-2003
			NO 20020765 A	17-04-2002
WO 9920275	A	29-04-1999	AU 9696198 A	10-05-1999
			BG 104432 A	29-12-2000
			BR 9814087 A	03-10-2000
			CA 2306825 A1	29-04-1999
			CN 1302206 T	04-07-2001
			EP 1030665 A1	30-08-2000
			HU 0101022 A2	28-10-2001
			JP 2001520193 T	30-10-2001
			NO 20001962 A	16-06-2000
			NO 20003107 A	26-07-2000
			PL 344977 A1	19-11-2001
			WO 9920275 A1	29-04-1999
			US 6376512 B1	23-04-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/B 03/02598

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9920275	A	ZA 9809465 A	17-04-2000
EP 0802186	A	22-10-1997	
		DE 19615263 A1	23-10-1997
		AT 197794 T	15-12-2000
		CA 2202704 A1	18-10-1997
		DE 59702677 D1	04-01-2001
		DK 802186 T3	27-12-2000
		EP 0802186 A1	22-10-1997
		ES 2153141 T3	16-02-2001
		GR 3035371 T3	31-05-2001
		JP 10059915 A	03-03-1998
		PT 802186 T	30-04-2001
		US 5750783 A	12-05-1998
US 6306854	B1	23-10-2001	
		AU 6350699 A	08-05-2000
		EP 1149063 A2	31-10-2001
		WO 0023407 A2	27-04-2000
		JP 2002527496 T	27-08-2002